Page last updated: 2024-12-05

estrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5870
CHEMBL ID1405
CHEBI ID17263
SCHEMBL ID21702
MeSH IDM0007798

Synonyms (256)

Synonym
MLS002695951
j3z ,
(9beta,13alpha)-3-hydroxyestra-1,3,5(10)-trien-17-one
BIDD:ER0145
3-hydroxy-estra-1,3,5(10)-trien-17-one
LMST02010004
MLS001077340
AB00382990-17
AB00382990-16
BRD-K81839095-001-04-6
gtpl2818
aquest
CHEBI:17263 ,
estra-1,3,5(10)-trien-17-one, 3-hydroxy-
MEGXM0_000444
SGCUT00128
EU-0100513
estrone, >=99%
oestrone [steroidal oestrogens]
estrogenic substance
ccris 285
nsc 9699
unden (pharmaceutical) (van)
natural estrogenic substance-estrone
brn 1915077
e(sub 1)
hsdb 3324
einecs 200-164-5
estrone (jan/usp/inn)
D00067
estrone (tn)
PRESTWICK3_000914
crystogen
fem-o-gen
follestrine
hormestrin
oestroform
hiestrone
estron
ketohydroxyestrin
endofolliculina
kestrone
crinovaryl
kolpon
oestrin
ketodestrin
thelykinin
folisan
femidyn
oestroperos
follicunodis
mestronaq
solliculin
estrusol
cristallovar
menformon
ovifollin
folikrin
hormofollin
nsc-9699
thelestrin
tokokin
estrone-a
theelin
menagen
follestrol
thynestron
disynformon
estrugenone
folipex
wynestron
unden
glandubolin
hormovarine
aquacrine
perlatan
destrone
oestrone
femestrone injection
cas-53-16-7
PRESTWICK2_000914
BPBIO1_000868
SMP1_000123
BSPBIO_000788
NCGC00179433-01
NCGC00179433-03
NCGC00179433-02
(13s)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6h-cyclopenta[a]phenanthren-17(14h)-one
ACON0_000083
SPECTRUM5_002047
LOPAC0_000513
ACON1_000122
3-hydroxy-17-keto-estra-1,3,5-triene
3-hydroxy-17-keto-oestra-1,3,5-triene
3-hydroxyestra-1,3,5(10)-triene-17-one
estra-1(10),2,4-trien-17-one, 3-hydroxy-
estrona [inn-spanish]
cmc_13458
delta-1,3,5-estratrien-3-beta-ol-17-one
estrona [spanish]
folliculine benzoate
oestronum
3-hydroxy-oestra-1,3,5(10)-trien-17-one
estronum [inn-latin]
ovex (tablets)
delta-1,3,5-oestratrien-3beta-ol-17-one
delta-1,3,5-estratrien-3beta-ol-17-one
1,3,5(10)-oestratrien-3-ol-17-one
delta-1,3,5-oestratrien-3-beta-ol-17-one
folliculine
1,3,5(10)-estratrien-3-ol-17-one
ketohydroxyoestrin
AB00382990
estrovarin
folliculin
3-hydroxy-1,3,5(10)-estratrien-17-one
3-hydroxyl-1,3,5(10)-estratien-17-one
hydroxyestrones
C00468
estrol
53-16-7
estrone ,
(8r,9s,13s,14s)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one
3-hydroxyestra-1,3,5(10)-trien-17-one
TO_000049
estrone, meets usp testing specifications
DB00655
NCGC00023643-06
NCGC00023643-05
MLS000028475 ,
smr000058338
PRESTWICK1_000914
PRESTWICK0_000914
SPBIO_002977
NCGC00023643-04
NCGC00023643-03
[2,4,6,7-3h]-estrone
(1s,10r,11s,15s)-5-hydroxy-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-trien-14-one
chembl1405 ,
estrone (e1)
[2,4,6,7-3h]-e1
bdbm17289
E 9750 ,
HMS2090E22
86C77018-146D-4603-ACEA-CA0D8C4F1E2C
AC-1395
NCGC00023643-10
BMSE000549
estradiol metabolite e1
way 164397
1,3,5-estratrien-3-ol-17-one
folliculinum
e0026 ,
HMS1570H10
STK801833
AKOS005622512
NCGC00023643-13
NCGC00023643-12
NCGC00023643-07
NCGC00023643-08
NCGC00023643-09
NCGC00023643-11
HMS2097H10
HMS3261H07
AKOS007930641
NCGC00257402-01
dtxsid4022367 ,
dtxcid402367
tox21_303651
NCGC00258926-01
tox21_113567
tox21_201375
CCG-204604
HMS2232O15
unii-2di9ha706a
3-08-00-01171 (beilstein handbook reference)
2di9ha706a ,
estronum
ec 200-164-5
estrone [usp:inn:ban]
LP00513
(8r,9s,13s,14s)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17h-cyclopenta(a)phenanthren-17-one
estrone [usp monograph]
estrone [inn]
estrone [hsdb]
estrone [who-dd]
estradiol hemihydrate impurity a [ep impurity]
estrone [usp-rs]
estrone [mart.]
estrone [orange book]
estrone [jan]
ethinylestradiol impurity c [ep impurity]
estrone [mi]
folliculinum [hpus]
estrone [vandf]
S1665
BBL033470
BL-090
HY-B0234
estrone dl-form [mi]
19973-76-3
x9xka379t9 ,
estrone, (+/-)-
unii-x9xka379t9
estra-1,3,5(10)-trien-17-one, 3-hydroxy-, (+/-)-
(+/-)-oestrone
(+/-)-estrone
SCHEMBL21702
NCGC00023643-15
tox21_113567_1
(+)-estrone
3-hydroxy-estra-1,3,5(10)-triene-17-one
tox21_500513
NCGC00261198-01
MLS006011890
Q-201073
(8r,9s,13s,14s)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17h-cyclopenta[a]phenanthren-17-one
OPERA_ID_330
AB00382990_18
sr-01000000085
SR-01000000085-3
estrone, united states pharmacopeia (usp) reference standard
estrone, vetranal(tm), analytical standard
estrone, european pharmacopoeia (ep) reference standard
EN300-120636
(1s,10r,11s,15s)-5-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-trien-14-one
estrone, pharmaceutical secondary standard; certified reference material
estrone 1.0 mg/ml in methanol
estrone 100 microg/ml in acetonitrile
SR-01000075867-1
sr-01000075867
HMS3714H10
d1,3,5(10)-estratrien-3-ol-17-one
3-hydroxyoestra-1,3,5(10)-trien-17-one
DS-6316
Q414986
BCP13336
BRD-K81839095-001-30-1
SDCCGSBI-0050497.P002
NCGC00023643-22
(8r,13s)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-cyclopenta[a]phenanthren-17-one
NCGC00023643-16
estrone (standard)
HY-B0234R
CS-0694877
Z1530425070
estrona (inn-spanish)
estrone1516
g03cc04
estronum (inn-latin)
estrone (usp:inn:ban)
ethinylestradiol impurity c (ep impurity)
estrone (usp-rs)
estrone (mart.)
estrone (usp monograph)
g03ca07

Research Excerpts

Overview

Estrone (E1) is a common environmental contaminant found in rivers and streams due to the farming of animals, such as swine and cattle. Estrone is a relatively abundant hormone widely distributed in tissues of animal and plant origin.

ExcerptReferenceRelevance
"Estrone (E1) is a common environmental contaminant found in rivers and streams due to the farming of animals, such as swine and cattle. "( Chronic estrone exposure affects spermatogenesis and sperm quality in zebrafish (Danio rerio).
Bazzoli, N; Miranda, TGR; Moreira, DP; Ribeiro, YM; Rizzo, E; Weber, AA, 2023
)
2.79
"Estrone is a representative steroid estrogen contaminant that has been detected in effluents from sewage treatment facilities, as well as in surface and ground waters. "( Chemisorption of estrone in nylon microfiltration membranes: Adsorption mechanism and potential use for estrone removal from water.
Gao, W; Han, J; Hu, J; Qiu, W, 2012
)
2.16
"Estrone is a common component of hormone replacement therapies, but research shows that 17β-estradiol may have a greater positive impact on cognition."( 17β-Estradiol, but not estrone, increases the survival and activation of new neurons in the hippocampus in response to spatial memory in adult female rats.
Barha, CK; Galea, LA; McClure, RE, 2013
)
1.42
"Estrone is a powerful growth-inducing hormone that is present in milk, mainly in the form of fatty acid esters, at concentrations that promote growth in experimental animals. "( Technical note: Measurement of total estrone content in foods. Application to dairy products.
Alemany, M; Fernández-López, JA; Ferrer-Lorente, R; García-Peláez, B; Gómez-Ollés, S; Remesar, X, 2004
)
2.04
"Estrone was confirmed to be a degradation product of 17beta-estradiol; however, estrone was not further degraded during the course of experiments."( 17beta-estradiol-degrading bacteria isolated from activated sludge.
Chu, KH; Roh, H; Yu, CP, 2007
)
1.06
"Estrone is a natural estrogen detected in sewage treatment works effluents and in estuarine waters. "( Effects of estrone on full life cycle of Java medaka (Oryzias javanicus), a new marine test fish.
Fujii, K; Imai, S; Koyama, J, 2007
)
2.17
"Estrone is a relatively abundant hormone widely distributed in tissues of animal and plant origin. "( Estrone in food: a factor influencing the development of obesity?
Alemany, M; Fernández-López, JA; Ferrer, E; Masanés, RM; Remesar, X; Tang, V; Torregrosa, C; Virgili, J, 1999
)
3.19

Effects

Estrone has been identified as an important potential endocrine-disrupting compound. Oestrone has been found to depress the incorporation of tritiated thymidine, proline and histidine in human skin in vitro.

ExcerptReferenceRelevance
"Estrone has been identified as the major form of estrogen in the environment; therefore, this study is focused on the evaluation of the degree of mineralization and fate of E1 in a simulated poultry litter and cow manure runoff water."( Mineralization and Biotransformation of Estrone in Simulated Poultry Litter and Cow Manure Runoff Water.
Aga, DS; Guardian, MGE, 2019
)
1.5
"Estrone has attenuated both pro- and anti-apoptotic NMDA-induced changes in rat primary neuronal cultures acting independently of estrogen receptors, as detected with ICI 182, 780."( Effects of estrone on N-methyl-D-aspartic acid- and staurosporine-induced changes in caspase-3-like protease activity and lactate dehydrogenase-release: time- and tissue-dependent effects in neuronal primary cultures.
Kajta, M; Kupiec, T; Lasoń, W, 2004
)
1.43
"Estrone has been identified as an important potential endocrine-disrupting compound, so that sensitive and reliable analytical methods are required for its determination and the assurance of human health. "( Separation and determination of estrone in environmental and drinking water using molecularly imprinted solid phase extraction coupled with HPLC.
Fang, G; He, J; Wang, S; Xu, Z; Zhang, Y, 2008
)
2.07
"Oestrone has been found to depress the incorporation of tritiated thymidine, proline and histidine in human skin in vitro. "( A pharmacological effect of oestrone on human epidermis.
Marks, R; Shahrad, P, 1977
)
1.46

Actions

Estrone did not cause any mutagens in the test used. Estrone was lower in cows with parturient paresis.

ExcerptReferenceRelevance
"Estrone did not cause any mutagens in the test used."( In vitro synthesis of 16 alpha-hydroxyestrone by female rat liver microsomes: its possible role in the etiology of breast cancer.
Arts, CJ; de Bie, AT; van den Berg, H; Wilmer, JW, 1990
)
1.27
"Acyl-estrone levels were lower than expected in most obese women when compared to those of controls, suggesting an altered availability or function of this hormone."( Plasma acyl-estrone levels are altered in obese women.
Alemany, M; Bullo, M; Cabot, C; Fernández-López, JA; García-Lorda, P; Masanés, R; Salas-Salvadó, J, 2000
)
1.14
"Estrone was lower in cows with parturient paresis."( Estrogen in plasma of parturient paretic and normal cows.
Falk, DE; Ross, RH; Sasser, RG, 1979
)
0.98

Treatment

Estrone treatment increased proliferation in mammary epithelial cells at days 3 and 7, and peaked by day 11 of estrone exposure. Oestrone treatment also had no effect on plasma and liver lipid peroxides.

ExcerptReferenceRelevance
"Estrone treatment produced a biphasic, concentration-dependent relationship with proliferation and tube formation and relatively no effect on hECFC migration at any concentration."( Distinct roles of estrone and estradiol in endothelial colony-forming cells.
Greene, AS; Ivory, A, 2023
)
1.97
"Estrone treatment simultaneously reduced the incidence of bladder changes to approximately 50 per cent although estrone alone had no effect on bladder weights."( Progressive hyperplastic lesions of the bladder uroepithelium after hormone stimulation in Nb rats.
Noble, RL, 1981
)
0.98
"Estrone treatment increased proliferation in mammary epithelial cells at days 3 and 7, and peaked by day 11 of estrone exposure."( Estrone-induced cell proliferation and differentiation in the mammary gland of the female Noble rat.
Holland, MB; Roy, D, 1995
)
2.46
"Estrone treatment increased (P < .01) plasma and endometrial tissue estrone concentrations."( Effect of estrone treatment from day 30 to 45 of pregnancy on endometrial protein secretion and uterine capacity.
Christenson, RK; Vallet, JL, 1994
)
1.41
"Oestrone treatment also had no effect on plasma and liver lipid peroxides."( Effect of oestrone on the natural killer (NK) cell activity, antioxidant status and tumour growth in athymic mice xenografted with human tumours.
Calop, J; Coudray, C; Favier, A; Fernandes-Carlos, T; Gauchez, AS; Guiraud, P; Jacrot, M; Riondel, J,
)
1.14
"Estrone and estradiol treatments increased both plasma and endometrial concentrations of estrone (P < .01 except endometrium for P gilts) and estradiol (P < .01, respectively)."( The effect of estrone and estradiol treatment on endometrial total protein, uteroferrin, and retinol-binding protein secretion during midpregnancy or midpseudopregnancy in swine.
Christenson, RK; Vallet, JL, 1996
)
1.38
"Estrone treatment increased the growth in height and width of the cartilage layers of the proximal epiphyses and inhibited the growth in height of the distal epiphyseal cartilage of earth gravity chicks."( Responses of articular and epiphyseal cartilage zones of developing avian radii to estrone treatment and a 2-G environment.
Kossler, T; Negulesco, JA, 1978
)
1.2
"Estrone treatments of 0.4 mg administered daily to hypergravity-exposed animals over a week-long period resulted in greater length of fracture callus and increased rate of growth of the proximal epiphyseal diameter of both intact and fractured bones."( Effects of increased earth gravity and estrone treatment on intact and healing avian radii.
Negulesco, JA, 1977
)
1.25
"Estrone or estriol treatment resulted in chemotactic activity greater than control but less than estradiol."( Estrogen regulation of an eosinophil chemotactic factor in the immature rat uterus.
Howe, RS; Lee, YH; Lyttle, CR; Sha, SJ; Sheehan, DM; Teuscher, C, 1989
)
1
"Estrone-treated db/db mice were similar to untreated mutants in exhibiting hyperphagia and marked obesity."( Estrone treatment dissociates primary versus secondary consequences of "diabetes" (db) gene expression in mice.
Leiter, EH; Lipson, LG; Premdas, FH; Prochazka, M, 1986
)
2.44
"Treatment with estrone, but not 17β-estradiol, and HSD17B14 overexpression both stimulate an EMT, matrigel invasion, and lung, bone, and liver metastasis in estrogen-receptor-positive (ER+) breast cancer models, while HSD17B14 knockdown reverses the EMT."( Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Diaz-Ruano, AB; Ince, TA; Nunes de Paiva, V; Picon-Ruiz, M; Qureshi, R; Sho, M; Slingerland, J; Van Booven, D, 2022
)
2.5
"Treatment of estrone derived A-ring diepoxyalcohol with the Ac(2)O-TMSOTf system at the ambient temperature led to acetylation, while at the reflux temperature the acid-catalysed rearrangement took place affording the spiro-compound."( Estrone derived steroidal diepoxide: biologically active compound and precursor of a stable steroidal A,B-spiro system.
Csanadi, J; Gasic, MJ; Juranic, Z; Kop, T; Milic, D; Solaja, B; Zizak, Z, 2009
)
2.15
"On-treatment oestrone levels were higher in non-responders to treatment."( Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983
)
0.61
"Pre-treatment with estrone (250-1000 micrograms/kg) at 24 and 2 hours before kainate (40 mg/kg) administration significantly decreased both the percentage of animals with clonic seizures and their mortality (the latter at a dose of 1000 micrograms/kg only)."( Estrone, but not 17 beta-estradiol, attenuates kainate-induced seizures and toxicity in male mice.
Budziszewska, B; Jaworska-Feil, L; Kajta, M; Kubera, M; Lasoń, W; Leśkiewicz, M, 2001
)
2.07

Toxicity

ZEN and its reductive metabolite α-zearalenol (α-ZEL) are often compared to those of 17β-estradiol (E2) and estrone (E1) Six novel conjugates were prepared via introducing RGD-tetrapeptides into both 3- and 17-positions of estradiol.

ExcerptReferenceRelevance
"Change in bone mineral density, lipoprotein metabolism, climacteric symptoms, and adverse effects."( Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects.
Alexandersen, P; Byrjalsen, I; Christiansen, C, 2000
)
0.69
" The results showed that NMDA (1 mM) had toxic effect on the rat cortical neurons on 12, but not on 7 day in vitro."( Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors.
Bień, E; Kajta, M; Lasoń, W; Marszał, M,
)
0.43
" The incidence and severity of adverse events were assessed by physical examination and patient reporting."( Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V, 2004
)
0.32
" All drug-related adverse events were grades 1 or 2; none was unexpected."( Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V, 2004
)
0.32
" DNQX (10 microM), an AMPA/kainate receptor antagonist, partly attenuated the toxic effects of QA, whereas LY 367 385 (100 microM), a selective mGluR1a antagonist, completely reversed the above effect."( Effects of estrone on quisqualate-induced toxicity in primary cultures of rat cortical neurons.
Kajta, M; Kubera, M; Lasoń, W; Marszał, M, 2005
)
0.72
" These data suggest that ethanol withdrawal can be created in HT22 cells in a manner that is more toxic than ethanol exposure and that ZYC26 is a more potent cytoprotectant than 17beta-estradiol against cell death and oxidative damage induced by ethanol withdrawal."( A nonfeminizing estrogen analog protects against ethanol withdrawal toxicity in immortalized hippocampal cells.
Jung, ME; Simpkins, JW; Wilson, AM, 2006
)
0.33
"To explore the structural dependence of the oral potency and side effect of estrogen-RGD peptide conjugates, here six novel conjugates were prepared via introducing RGD-tetrapeptides into both 3- and 17-positions of estradiol, and introducing RGD-octapeptides into 3-position of estrone."( 3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
Li, C; Liu, J; Peng, L; Peng, S; Zhang, X; Zhao, M, 2009
)
0.53
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The adverse effects of ZEN and its reductive metabolite α-zearalenol (α-ZEL) are often compared to those of 17β-estradiol (E2) and estrone (E1)."( Genotoxicity and inactivation of catechol metabolites of the mycotoxin zearalenone.
Fleck, SC; Hildebrand, AA; Metzler, M; Müller, E; Pfeiffer, E, 2012
)
0.58
" We used intent-to-treat analysis (N = 224) and compliant analysis (>95%; N = 208) to assess circulating hormone concentrations, adverse events, and endometrial thickness (via transvaginal ultrasound)."( Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women.
Alekel, DL; Beer, BS; Genschel, U; Hanson, LN; Hofmann, H; Koehler, KJ; Kurzer, MS; Peterson, CT; Van Loan, MD, 2015
)
0.42
" We find no evidence of treatment effects on endometrial thickness, adverse events, or circulating hormone concentrations, most notably thyroid function, across a 3-year period."( Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women.
Alekel, DL; Beer, BS; Genschel, U; Hanson, LN; Hofmann, H; Koehler, KJ; Kurzer, MS; Peterson, CT; Van Loan, MD, 2015
)
0.42
" As both dietary vitamin D and calcitriol treatments inhibit breast estrogen synthesis and signaling, we hypothesized that vitamin D would be especially beneficial in mitigating the adverse effects of obesity on ER+BCa."( Vitamin D mitigates the adverse effects of obesity on breast cancer in mice.
Aggarwal, A; Albertelli, MA; Feldman, BJ; Feldman, D; Horst, RL; Krishnan, AV; Swami, S; Williams, J, 2016
)
0.43
" Daphnia magna acute toxicity assay, comet assay, cytokinesis-block micronucleus and E-screen assay were performed to assess whether the effluent reaching the main parameters of Chinese Discharge Standard (GB 16889-2008) still had toxic residues."( Advanced treatment of landfill leachate membrane concentrates: performance comparison, biosafety and toxic residue analysis.
Hong, M; Hou, C; Lu, G; She, S; Zhu, L, 2017
)
0.46
"The application of anticancer drugs during pregnancy is associated with placenta-related adverse pregnancy outcomes."( Toxicity of anticancer drugs in human placental tissue explants and trophoblast cell lines.
Eliesen, GAM; Greupink, R; Meijer, MH; Pertijs, J; Roeleveld, N; Russel, FGM; van den Broek, PHH; van Drongelen, J; van Hove, H, 2021
)
0.62
" However, due to the limitations of adverse reaction and lacking of targeting ability, the chemotherapy of ovarian cancer is still poorly effective."( Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs.
Guo, X; Jia, J; Liu, R; Miao, D; Pei, J; Shen, Y; Tang, H; Xie, Y; Zheng, Y; Zhu, M, 2022
)
2.16
"Efficient management of disguised toxic pollutants (DTPs), which can undergo microbial degradation and convert into more toxic substances, necessitates the collaboration of diverse microbial populations in wastewater treatment plants."( Identification of key degraders for controlling toxicity risks of disguised toxic pollutants with division of labor mechanisms in activated sludge microbiomes: Using nonylphenol ethoxylate as an example.
He, X; Jiang, J; Liu, P; Ouyang, Y; Wang, D; Yan, B; Zhang, XX, 2023
)
0.91
" Safety was measured by treatment emergent adverse events and changes in systemic laboratories and the endometrial bilayer width."( A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
Friend, D; Hatheway, J; Hull, ML; Mauck, C; Stuckey, B; Thurman, A; Zack, N, 2023
)
0.91
" All treatment emergent adverse events were mild or moderate and were distributed similarly among IVR1 versus IVR2 users."( A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
Friend, D; Hatheway, J; Hull, ML; Mauck, C; Stuckey, B; Thurman, A; Zack, N, 2023
)
0.91
"Both DARE-HRT1 IVRs were safe and released E2 in systemic concentrations, which were in the low, normal premenopausal range."( A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
Friend, D; Hatheway, J; Hull, ML; Mauck, C; Stuckey, B; Thurman, A; Zack, N, 2023
)
0.91

Pharmacokinetics

Study was conducted to determine the effects of TDS application site (buttocks versus abdomen) and early TDS replacement on estradiol and estrone concentrations. The maximum serum concentration, Cmax, of the second absorption or recirculation of oestrone was 20% that of the first.

ExcerptReferenceRelevance
" Pharmacokinetic data demonstrated tha the drug was rapidly absorbed after oral dosing, with peak plasma concentrations achieved in median times of 1 and 2 h, respectively, for the 2- and 8-mg twice daily treatment regimens."( The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition.
Demers, L; Entwistle, EA; Kochak, GM; Lipton, A; Mangat, S; Mulagha, MT; Santen, RJ, 1990
)
0.28
"Preovulatory bovine follices (n = 73) were collected at different times after the onset of oestrus until shortly before ovulation, which occurred at 24 +/- 1 X 4 h after the peak concentration of LH in the peripheral blood."( Steroid and pituitary hormone concentrations in the fluid of preovulatory bovine follicles relative to the peak of LH in the peripheral blood.
Bevers, MM; Dieleman, SJ; Poortman, J; van Tol, HT, 1983
)
0.27
"Using constant infusion of unlabeled steroid, we have studied the metabolic clearance rate (MCR), half-life (T 1/2), and conversion ratio of androstenedione (A) into androgens and estrogens throughout human pregnancy."( The metabolism of androstenedione in human pregnancy: the use of constant infusion of unlabeled steroid to assess its metabolic clearance rate, its production rate, and its conversion into androgens and estrogens.
Belisle, S; Brault, J; Lehoux, JG, 1980
)
0.26
" The data suggests that among the three esters studied, the valerate provides the most predictable pharmacokinetic behaviour."( A comparison of the pharmacokinetic properties of three estradiol esters.
Diczfalusy, E; Landgren, BM; Oriowo, MA; Stenström, B, 1980
)
0.26
" After micronized 17 beta-oestradiol however, there was a 2-3-fold increase in the ratio at Cmax and slower elimination of 17 beta-oestradiol from plasma, which may be due to the fact that high serum oestrone levels may serve as a reservoir, since both a metabolite and also a precursor of 17 beta-oestradiol."( Pharmacokinetic evaluation of oral 17 beta-oestradiol and two different fat soluble analogues in ovariectomized women.
Cullberg, G; Hedner, T; Schubert, W, 1993
)
0.47
" The clearance of EMATE from plasma followed a bi-phasic curve, showing an initial half-life of 30 min, followed by a slower half-life of 4 h 30 min."( Pharmacokinetics of oestrone-3-O-sulphamate.
Hidalgo Aragones, MI; Parish, D; Potter, BV; Pouton, CW; Purohit, A; Reed, MJ; Sahm, UG, 1996
)
0.61
" This two-period crossover study was conducted to determine the effects of TDS application site (buttocks versus abdomen) and early TDS replacement on estradiol and estrone concentrations, and to quantify intersubject and intrasubject pharmacokinetic variability."( Pharmacokinetics of a 7-day 17 beta-estradiol transdermal delivery system: effect of application site and repeated applications on serum concentrations of estradiol and estrone.
Abel, RB; Boyd, RA; Eldon, MA; Forgue, ST; Sedman, AJ; Yang, BB, 1996
)
0.68
"To investigate the pharmacokinetic profiles of different doses of micronized 17 beta-estradiol administered by oral or sublingual routes."( Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol.
Bates, GW; Blauer, KL; Hansen, M; Lobo, R; Price, TM; Stanczyk, F, 1997
)
0.3
" We calculated pharmacokinetic parameters for estradiol (E2) and estrone (E1) of maximum serum concentration, time to maximum serum concentration, terminal half-life, area under the concentration curve, and oral clearance."( Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol.
Bates, GW; Blauer, KL; Hansen, M; Lobo, R; Price, TM; Stanczyk, F, 1997
)
0.53
" The absolute Cmax values were similar (255 pg/ml after tablet administration and 279 pg/ml after suspension), bioequivalence also in regard to Cmax was proven."( [Comparison of the relative bioavailability and pharmacokinetics of estrone after oral administration of esterified estrogens in a tablet formulation and an aqueous suspension].
Degen, J; Seiberling, M; Thomann, P; Völter-Erhardt, H; Wölke, E, 1997
)
0.53
"The pharmacokinetic pattern of estradiol (CAS 50-28-2) and of estrone (CAS 53-16-7) during and after application of three strengths of a new transdermal estradiol patch (Dermestril) with active matrix was investigated in a cross-over study in 24 women in natural or surgical menopause."( Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix.
Gualano, V; Guillaume, M; Mignot, A; Renoux, A; Rovati, LC; Setnikar, I; Thebault, JJ, 1997
)
0.81
"The pharmacokinetic patterns of estradiol (CAS 50-28-2) and of estrone (CAS 53-16-7) were investigated in 18 women in natural or surgical menopause during the application of a new estradiol transdermal patch with active matrix and without absorption enhancers designed for epicutaneous applications of 7 days (hereinafter called "patch 7D")."( Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Hilgenstock, C; Rovati, LC; Setnikar, I; Vens-Cappell, B, 1998
)
0.81
" The maximum serum concentration, Cmax, of the second absorption or recirculation of oestrone was 20% that of the first, and the Cmax of the third circulation was 50% that of the second."( Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women.
Timmer, CJ; Vree, TB, 1998
)
0.52
" Mean estradiol Cmax values of 39."( Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women.
Börner, A; Breitbarth, H; Koytchev, R; Mayer, O; Mellinger, U; Zimmermann, H, 1998
)
0.3
" The pharmacokinetic study of the drugs was performed at the seventh, ninth and 14th day in Gelestra treated women and at the first, third and second day in Estraderm TTS 50 treated women."( Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Bigini, C; Melis, GB; Nannipieri, F; Paoletti, AM; Pilia, I, 2001
)
0.31
"A multiple-dose, placebo-controlled, randomized pharmacokinetic study was performed in 15 early (i."( Evaluation of single- and multiple-dose pharmacokinetics of synthetic conjugated estrogens, A (Cenestin) tablets: a slow-release estrogen replacement product.
Phelps, KV; Roy, R; Stevens, RE, 2002
)
0.31
"These pharmacokinetic results indicate that the generic tablets do not have the modified-release characteristics of Conpremin tablets."( Pharmacokinetic comparison between Conpremin (Premarin) and a generic preparation of conjugated estrogens.
Arteaga, E; Villaseca, P, 1998
)
0.3
" Clinical trials combining tamoxifen with letrozole or anastrazole have shown minor pharmacokinetic drug interactions."( Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005
)
0.33
" Blood was collected for pharmacokinetic analysis after at least 4 months of receiving 20 mg tamoxifen daily."( Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005
)
0.33
"There is no pharmacokinetic interaction between tamoxifen and exemestane."( Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005
)
0.33
" There were no significant changes in the pharmacokinetic parameters of ticlopidine when it was coadministered with ginkgo biloba."( The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine.
Huang, JD; Lai, ML; Lu, WJ, 2006
)
0.33
" Pharmacokinetic and pharmacodynamic data for plasma estrogens, raloxifene, exemestane, and their metabolites were collected at the end of single-agent therapy and during combination therapy."( Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA, 2008
)
0.35
"To determine steady-state plasma concentrations and the pharmacokinetic profile of the essential components of synthetic conjugated estrogens, B (SCE-B), particularly total estrone and delta8,9-dehydroestrone (DHE), after oral administration of a modified-released tablet."( Pharmacokinetics of a modified-release estrogen tablet.
Bhamra, R; Kaercher, U; Oleary, CM,
)
0.32
"25-mg tablets achieved consistent pharmacokinetic parameters and steady-state levels when administered to healthy postmenopausal women."( Pharmacokinetics of a modified-release estrogen tablet.
Bhamra, R; Kaercher, U; Oleary, CM,
)
0.13
"A randomized, parallel-design study was conducted to determine the pharmacokinetic profile of synthetic conjugated estrogens A (SCE-A) vaginal cream (0."( A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream.
Bhamra, RK; DiLiberti, CE; Hendy, CH; Jenkins, RG; Liu, JH; Margolis, MB, 2011
)
0.37
" The objectives of this study were to examine the pharmacokinetic profile of letrozole in Japanese subjects and to identify factors that influence variability in the pharmacokinetics of letrozole using population pharmacokinetic (PPK) analysis."( Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Horie, T; Shitara, Y; Tanii, H, 2011
)
0.37
" Estrone, estrone sulfate, and estradiol in plasma were measured as pharmacodynamic markers."( Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.
Horie, T; Shitara, Y; Tanii, H, 2011
)
1.28
" Pharmacokinetic results suggest that simvastatin is not likely to compromise the activity of anastrozole."( Effect of simvastatin on the pharmacokinetics of anastrozole.
Bao, T; Blackford, AL; Stearns, V, 2012
)
0.38
"5 mg) was administered daily to healthy women (18-50 years, n=23) for 24 days; blood samples for pharmacokinetic analysis were obtained on Day 24 and again, after a 10-day pill-free interval, on Day 35 after a single dose."( Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women.
Gerrits, MG; Peeters, PA; Post, TM; Schnabel, PG, 2013
)
0.39
"5 h (t(max)); the mean±SD elimination half-life (t(½)) was 45."( Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women.
Gerrits, MG; Peeters, PA; Post, TM; Schnabel, PG, 2013
)
0.39
"These data demonstrate that NOMAC/E2 has a pharmacokinetic profile consistent with once-daily dosing."( Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women.
Gerrits, MG; Peeters, PA; Post, TM; Schnabel, PG, 2013
)
0.39
"Two open-label, randomized, two-period, crossover studies were performed to determine the safety, delivery rates, and pharmacokinetic properties of a combination estradiol (E2)/levonorgestrel (LNG) transdermal delivery system (TDS)."( Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Bourg, D; Bourg, L; Harrison, LI; Karara, AH; Melikian, AP; Morrison, D; Poola, N; Zurth, C, 2014
)
0.4
" Baseline-corrected and uncorrected serum TT and fT pharmacokinetic parameters (AUC0-24, C avg, Cmax, and Tmax) were calculated using a standard model-independent approach."( Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women.
Bell, RJ; Davis, SR; Fooladi, E; Reuter, SE; Robinson, PJ, 2015
)
0.42
" The primary pharmacokinetic endpoints were Cmax, AUC(0-t), and AUC(0-inf) for the test and reference products, assessed for bioequivalence using the scaled average bioequivalence or unscaled average bioequivalence method."( Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.
Amadio, JM; Bernick, B; Bon, C; Mirkin, S; Pickar, JH, 2015
)
0.42
" All AUC and Cmax parameters met bioequivalence criteria for all analytes (estradiol, progesterone, and estrone), except Cmax for total estrone."( Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.
Amadio, JM; Bernick, B; Bon, C; Mirkin, S; Pickar, JH, 2015
)
0.63
" An independent whole-body physiology-based pharmacokinetic (WB-PBPK) simulation model of NOMAC based on an independent Phase 3 dataset was used to scale NOMAC concentration-time plots to adolescents."( Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.
de Greef, R; Gerrits, M; Kerbusch, T; Post, TM, 2016
)
0.43
" No statistically significant differences were observed between the adolescent and adult groups for the clinically evaluated NOMAC PK parameters [maximum concentration (Cmax), area under the curve (AUC) and half-life (t1/2)]."( Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.
de Greef, R; Gerrits, M; Kerbusch, T; Post, TM, 2016
)
0.43
"The design, synthesis, in vitro inhibitory potency, and pharmacokinetic (PK) profiles of Ko143 analogs are described."( Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Chmielecki, J; Chuang, BC; Guan, MY; Li, Y; Liao, M; Plesescu, M; Prakash, SR; Woo, J; Xia, CQ; Yang, JJ, 2016
)
0.43
" Significantly lower systemic levels of estradiol, estrone, and estrone sulfate at both doses of the test product were observed compared with equivalent doses of the reference product, with lower AUC0-24 and Cmax and earlier tmax."( Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.
Amadio, JM; Bernick, BA; Mirkin, S; Pickar, JH, 2016
)
0.69
"Oral E2 administered sublingually has a different pharmacokinetic profile, with higher serum E2 levels and AUC (0-8 hours) than traditionally administered oral E2."( Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women.
Doll, E; Gunsolus, I; Lamberton, N; Sarvaideo, JL; Tangpricha, V; Thorgerson, A, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"We randomly assigned 278 healthy, early postmenopausal women to receive either 2 mg 17beta-estradiol sequentially combined with 25 microg gestodene (group 2/25s), 2 mg estradiol sequentially combined with 50 microg gestodene (group 2/50s), 1 mg estradiol sequentially combined with 25 microg gestodene (group 1/25s), 1 mg estradiol continuously combined with 25 mg gestodene (group 1/25c), or placebo."( Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss.
Bjarnason, NH; Byrjalsen, I; Christiansen, C; Haarbo, J; Hassager, C, 2000
)
0.31
" Then, to explore the possibility of OATP1B1-mediated drug-drug interaction, we checked the inhibitory effects of various drugs on the pitavastatin uptake in OATP1B1-expressing cells and evaluated whether the in vitro inhibition was clinically significant or not."( Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
Hirano, M; Maeda, K; Shitara, Y; Sugiyama, Y, 2006
)
0.33
"Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic elimination of many drugs and potentially associated drug-drug interactions."( Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Brun, ME; Funk, C; Noé, J; Portmann, R, 2007
)
0.34
" Plasma estrogen concentrations were suppressed below the lower limit of detection by exemestane as monotherapy and when administered in combination with raloxifene."( Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA, 2008
)
0.35
" Because OATP2B1 exhibits an increasing number of drug substrates, including several statins, alterations of its function by PIs could result in clinically significant drug-drug interactions in the intestine."( pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.
Bendayan, R; Kis, O; Ramaswamy, M; Zastre, JA, 2010
)
0.36
" We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors."( A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Abrams, TA; Blaszkowsky, LS; Chan, JA; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Regan, E; Sidor, C; Zhu, AX, 2011
)
0.37
" The authors evaluated the hormonal activities (estrogenic/anti-estrogenic activities, androgenic/anti-androgenic activities) and genotoxicity of various effluents from textile and dyeing plants, electronic and electroplate factories, pulp and paper mills, fine chemical factories, and municipal wastewater treatment plants in the Pearl River Delta region by using in vitro bioassays (yeast estrogen screen [YES]; yeast androgen screen [YAS]; and genotoxicity assay [umu/SOS]) combined with chemical analysis."( Assessment of hormonal activities and genotoxicity of industrial effluents using in vitro bioassays combined with chemical analysis.
Chen, F; Fang, YX; Liu, S; Yang, B; Ying, GG; Zhang, LJ; Zhao, JL, 2012
)
0.38
"To support drug development, the drug-drug interaction potential (DDI) of an investigational drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against simvastatin acid, atorvastatin, pravastatin, pitavastatin, fluvastatin, rosuvastatin and estrone 3-sulfate."( Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.
Butters, CJ; Elsby, R; Sharma, P; Smith, V; Surry, D, 2012
)
0.56
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" Site/sample heterogeneity was prevalent, in combination with generally high relative bioluminescence scores for oxidative stress (OH•)."( Profiling the biological effects of wastewater samples via bioluminescent bacterial biosensors combined with estrogenic assays.
Bazin, I; De Waard, M; Gu, MB; Ramuz, M; Seo, HB; Suehs, CM, 2017
)
0.46
"01 nM) in combination with low concentrations of GEN, DAI and EQ (0."( Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones.
Betschler, A; Früholz, R; Grgic, D; Marko, D; Novak, B; Varga, E, 2022
)
0.72

Bioavailability

Sulphamoylation of oestrogens enhances their potency and bioavailability. We have synthesized 2-methoxyoestrone-3-O-sulphamate (2-MeOEMATE) and compared its ability to inhibit the proliferation of breast cancer cells. Overall, transdermal application leads to higher bioavailability of estradiol compared with the oral use of estrone or estrone sulfate.

ExcerptReferenceRelevance
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."( Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977
)
0.26
"The bioavailability of 17 beta-estradiol valerate, free 17 beta-estradiol and Premarin was studied in 24 subjects suffering from secondary amenorrhea."( Bioavailability of natural estrogens in young females with secondary amenorrhea.
Schneider, WH; Spona, J, 1977
)
0.26
"Serum levels of cortisol (C), androstenedione (A), dehydroepiandrosterone (D), estrone (E1) and estradiol (E2) were chosen as parameters to compare the bioavailability of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in postmenopausal patients with advanced breast cancer."( Adrenal steroids as parameters of the bioavailability of MA and MPA.
Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990
)
0.51
" The bioavailability of 14C-radiolabeled progesterone administered nasally was found to be 100% of that of an iv dose."( Nasal absorption and metabolism of progesterone and 17 beta-estradiol in the rat.
Bawarshi-Nassar, RN; Crooks, PA; Hussain, AA,
)
0.13
" Association of germfree rats with the cecal volume-reducing flora did not change the cecal absorption rate of estrone-3-sulfate, but shortened the 50% small intestinal transit time of [14C]PEG from 10 to 3 h; a value also found in conventional rats."( Influence of a cecal volume-reducing intestinal microflora on the excretion and entero-hepatic circulation of steroids and bile acids.
Caenepeel, P; Eyssen, H; Robben, J; Van Eldere, J, 1988
)
0.49
" Our results, although preliminary, suggest that aminoglutethimide is a potent inducer of aminoglutethimide metabolism, thereby producing a significant reduction in plasma bioavailability of oestrone sulphate."( Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Kvinnsland, S; Lønning, PE; Thorsen, T; Ueland, PM, 1987
)
0.46
" They also suggest that in future studies concerned with the absorption and bioavailability of topically applied chemicals, an assessment of the drug-metabolizing capabilities of the skin needs to be considered."( Skin absorption and cutaneous first pass metabolism of topical steroids: in vitro studies with mouse skin in organ culture.
Hall, J; Kao, J, 1987
)
0.27
" This study demonstrates that smoking exerts a powerful inducing effect on the 2-hydroxylation pathway of estradiol metabolism, which is likely to lead to decreased bioavailability at estrogen target tissues."( Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking.
Bradlow, HL; Fishman, J; Hershcopf, RJ; Michnovicz, JJ; Naganuma, H, 1986
)
0.27
" Comparison of "areas under the curve" obtained with the present preparations to similar previous studies on ethinyl oestradiol indicated that the bioavailability of the non-ethinyl oestrogens is by more than one order of magnitude less than that of ethinyl oestradiol after oral administration."( Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration.
Bolt, HM; Göser, R; Hochlehnert, G; Schindler, AE; Zwirner, M, 1982
)
0.52
" Comparison of areas under the curve obtained with the present preparations similar to previous studies on ethinyl estradiol indicated that the bioavailability of the nonethinyl estrogens is by more than 1 order of magnitude less than that of ethinyl estradiol after oral administration."( Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration.
Bolt, HM; Göser, R; Hochlehnert, G; Schindler, AE; Zwirner, M, 1982
)
0.52
" The rate of absorption is however very much reduced compared to the non-sulphated steroid."( Gastrointestinal absorption of estrone sulfate in germfree and conventional rats.
Back, DJ; Eyssen, HJ; Huijghebaert, S; Sim, SM, 1983
)
0.55
" Comparison of the absorption rates for estrone and the lysine estrone ester indicates that the absorption rate of the derivatives could be up to five orders of magnitude greater than that for the parent compound."( Improving intestinal absorption of water-insoluble compounds: a membrane metabolism strategy.
Amidon, GL; Elliott, RL; Leesman, GD, 1980
)
0.53
"Crystalline oestradiol-17 beta is poorly absorbed from the gastrointestinal tract."( Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particles sizes.
Englund, DE; Johansson, ED, 1981
)
0.26
" Overall, transdermal application leads to higher bioavailability of estradiol compared with the oral use of estrone/estrone sulfate or estradiol."( [Transdermal and oral hormone substitution with estrogens: a comparison].
Schindler, AE, 1995
)
0.5
" Results of this study confirm those of previous investigations which monitored the bioavailability of MOP with the use of serum progesterone measurements and showed that luteal phase progesterone concentrations can be attained easily."( Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay.
Bolaji, II; Fottrell, PF; O'Dwyer, E; Tallon, DF, 1993
)
0.29
" The purpose of the study was to determine the absolute bioavailability of orally administered E2 in a larger group of women and to assess the inter- and intraindividual variability of basic pharmacokinetic parameters of E2 and metabolically derived E1."( Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol.
Gansau, C; Kuhnz, W; Mahler, M, 1993
)
0.54
" The present data suggest that estrogen sulfates can play an important biological role in the target tissues of the fetus, and that the enzymatic mechanisms of the bioavailability of E2 for the biological responses of the hormone can be operated in the target tissue itself."( Transformation of estrone, estradiol, and estrone sulfate in uterine and vaginal isolated cells of fetal guinea pig. Effect of various antiestrogens in the conversion of estrone sulfate to estradiol.
Chetrite, G; Pasqualini, JR; Urabe, M, 1993
)
0.62
"Oral therapy with natural or synthetic estrogens, like ethinylestradiol, suffers from low, suboptimally defined bioavailability and excess hepatic estrogen actions."( Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application.
Elger, W; Hedden, A; Reddersen, G; Schneider, B; Schwarz, S, 1995
)
0.29
" Due to differences in patch design and composition, the rate of absorption was different between the two systems, with less fluctuating E2 plasma levels during application of the matrix system."( Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system.
Botta, L; Ezzet, F; Müller, P, 1996
)
0.29
" Patch 7D provided a similar bioavailability as patch 50 with regard to the rate and the extent of absorption of E2, as shown by the AUCs during the 7-day applications of one patch 7D compared to those during the 7-day applications of 2 patches 50."( Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Hilgenstock, C; Rovati, LC; Setnikar, I; Vens-Cappell, B, 1998
)
0.57
"The relative bioavailability of estradiol from two matrix transdermal delivery systems, Alora (0."( Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Bixler, C; Brezovic, C; Buch, A; Kelly, S; Powell, J; Sahota, R; Shen, L, 1998
)
0.3
"The aim of the study was to assess the bioavailability of estradiol (E2) following oral, single-dose administration of equimolar doses of three HRT preparations in a 3-way cross-over study in postmenopausal women."( Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study.
Geurts, TB; Timmer, CJ,
)
0.13
" As sulphamoylation of oestrogens enhances their potency and bioavailability we have synthesized 2-methoxyoestrone-3-O-sulphamate (2-MeOEMATE) and compared its ability to inhibit the proliferation of breast cancer cells with that of 2-methoxyoestrone (2-MeOE1)."( The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours.
Hejaz, HA; MacCarthy-Morrogh, L; Packham, G; Potter, BV; Purohit, A; Reed, MJ; Walden, L, 2000
)
0.83
"To study whether dose adjustments in transdermal estradiol gel treatment would result in proportional changes in estradiol bioavailability and concentrations."( Effect of dose on the absorption of estradiol from a transdermal gel.
Granander, M; Järvinen, A; Laine, T; Viitanen, A, 2000
)
0.31
"5 mg estradiol daily can be made with an anticipated effect in estradiol bioavailability and concentrations."( Effect of dose on the absorption of estradiol from a transdermal gel.
Granander, M; Järvinen, A; Laine, T; Viitanen, A, 2000
)
0.31
" The possibility does exist that the SHBG level increase and the IGF-I bioavailability decrease, caused by oral CEE, balance the increased estrogen stimulation on breast tissue."( Conjugated estrogens and breast cancer risk.
Ambroggio, S; Biglia, N; Campagnoli, C; Sismondi, P, 1999
)
0.3
"/Premarin) of bioavailability parameters indicated that all C(max) and t(max) values for the unconjugated and total E(1), Eq, 17beta-E(2), and 17beta-Eq fell outside the regulatory requirement that the 90% confidence intervals of GMRs of two products be within 80% and 125%."( Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women.
Aletebi, F; Bhavnani, BR; Martin, J; Milne, JK; Nisker, JA; Watson, L,
)
0.13
" Our results suggest a critical role for ER modulation and genistein bioavailability in the maintenance of the implants."( Pharmacologic, but not dietary, genistein supports endometriosis in a rat model.
Cotroneo, MS; Lamartiniere, CA, 2001
)
0.31
" This difference may be attributed to the higher dosage of oral E2 that is required because of the low bioavailability compared with the transdermal dosages."( Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women.
Hodis, HN; Mack, WJ; Paulson, RJ; Shoupe, D; Slater, CC; Stanczyk, FZ,
)
0.43
" Its applicability to the study of estrogen bioavailability and bioequivalence is suggested."( Reversed-phase liquid chromatographic method for estrogen determination in equine biological samples.
Lima, SB; Ribeiro Neto, LM; Verreschi, IT, 2001
)
0.31
" Both [4-14C]-17beta-estradiol and [4-14C]-estrone formed non-extractable residues, and soil-bound residues were only slowly mineralized, suggesting that their bioavailability was low."( Persistence of estrogenic hormones in agricultural soils: I. 17Beta-estradiol and estrone.
Bork, H; Colucci, MS; Topp, E,
)
0.62
"To determine the relative bioavailability of the estrogenic components of a generic brand of conjugated estrogens marketed in Chile in comparison to that of Conpremin (Premarin in the United States)."( Pharmacokinetic comparison between Conpremin (Premarin) and a generic preparation of conjugated estrogens.
Arteaga, E; Villaseca, P, 1998
)
0.3
"There is increasing evidence that dietary factors may play a role in the production, metabolism, and bioavailability of sex hormones and their impact on target tissues."( The specific role of isoflavones on estrogen metabolism in premenopausal women.
Allen, K; Cantor, A; Cox, CE; Kumar, NB; Riccardi, D, 2002
)
0.31
" The nasal and sublingual modes of administration rapidly convert estradiol into estrone, while the absorption rate through the cutaneous mode is even quicker, and subcutaneous implantation guarantees constant plasmatic levels for about 6 months."( [What happens in our patients' bodies to the steroid hormones we prescribe? Pt. 1. Estrogens].
Rozenbaum, H, 1981
)
0.49
" It also provides additional explanation why raloxifene has low bioavailability but a long half-life."( Disposition mechanisms of raloxifene in the human intestinal Caco-2 model.
Hu, M; Jeong, EJ; Lin, H, 2004
)
0.32
" We hypothesized that consumption of probiotic bacteria would alter fecal bacteria and enzymes involved in soy isoflavone metabolism, thereby increasing isoflavone bioavailability and enhancing the beneficial effects of soy on estrogen metabolism."( The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption.
Adlercreutz, H; Greany, KA; Kurzer, MS; Nettleton, JA; Thomas, W; Wangen, KE, 2005
)
0.57
" In summary, ergoloid mesylates is a more potent inhibitor of OATP-B than is ginkgo biloba, and it can reduce the oral bioavailability of drugs transported by OATP-B."( The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine.
Huang, JD; Lai, ML; Lu, WJ, 2006
)
0.33
" The primary objective of this study was the evaluation of the systematic bioavailability of estradiol and estrone and the pharmacokinetics of two of the most frequently used intravaginal estrogen preparations, namely Vagifem and Premarin cream."( Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
Bélanger, P; Bérubé, R; Côté, I; Cusan, L; Gomez, JL; Labrie, C; Labrie, F; Martel, C,
)
0.34
"1 mL g(-1)) this apparently did not control estrogen bioavailability since it showed no effects on hormone mineralization."( Factors controlling the biodegradation of 17beta-estradiol, estrone and 17alpha-ethinylestradiol in different natural soils.
Marschner, B; Stumpe, B, 2009
)
0.6
"The macrolide antibiotics azithromycin and clarithromycin are large molecular weight compounds that exhibit moderate to excellent oral bioavailability in preclinical species and humans."( Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.
Davis, CB; Dawson, PA; Garver, E; Han, C; Haywood, J; Lan, T; Rao, A, 2009
)
0.35
" Compounds that alter transport by one or both of these OATPs could potentially be used to target drugs to hepatocytes or improve the bioavailability of drugs that are cleared by the liver."( Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae).
Araya, JJ; Hagenbuch, B; Roth, M; Timmermann, BN, 2011
)
0.37
"4, suggesting that ABCG2 plays a role in limiting chlorothiazide bioavailability in humans."( ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions.
Abonyi, T; Bánsághi, S; Beéry, E; Erdő, F; Herédi-Szabó, K; Jani, M; Kis, E; Krajcsi, P; Makai, I; Márki-Zay, J; Rajnai, Z; Sziráki, I; Tóth, GK, 2012
)
0.38
" Furthermore, with the purpose of evaluating the bioavailability of PBRM and CC-156 injected subcutaneously (2."( A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan, D; Maltais, R; Poirier, D; Roy, J, 2012
)
0.58
" The objective of this study was to determine the fate of 17β-estradiol and 17β-trenbolone in two field sediments and to evaluate the corresponding bioavailability of the compounds to the fathead minnow (Pimephales promelas)."( Bioavailability and fate of sediment-associated trenbolone and estradiol in aquatic systems.
Bartelt-Hunt, SL; Cox, MB; Garcia, YA; Hernandez, R; Kolok, AS; Sangster, JL; Sivils, JC; Snow, DD; Zhang, Y, 2014
)
0.4
"This study aims to compare the pharmacokinetics and oral bioavailability of a capsule combining 17β-estradiol and progesterone in a non-peanut oil-containing formulation with those of widely used and approved separate formulations of estradiol and progesterone coadministered to healthy postmenopausal women."( Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.
Amadio, JM; Bernick, B; Bon, C; Mirkin, S; Pickar, JH, 2015
)
0.42
"The combination 17β-estradiol/progesterone product demonstrates bioavailability similar to those of the respective reference products of estradiol and progesterone."( Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.
Amadio, JM; Bernick, B; Bon, C; Mirkin, S; Pickar, JH, 2015
)
0.42
" This shift was not due to DOC being an antagonist itself or interfering with fluorescence measurements, but was due to DOC reducing the bioavailability of 17β-estradiol."( Understanding the implications of dissolved organic carbon when assessing antagonism in vitro: An example with an estrogen receptor assay.
Escher, BI; Leusch, FD; Neale, PA, 2015
)
0.42
" This implies that alterations in placental steroidogenesis and, subsequently, in the functionality or bioavailability of placental aromatase may be mechanistically involved in the pathophysiology of PE."( Placental Aromatase Is Deficient in Placental Ischemia and Preeclampsia.
Dobierzewska, A; España-Perrot, PP; Figueroa-Diesel, H; González, MI; Guzmán-Rojas, AM; Illanes, SE; Irarrazabal, CE; Monteiro, LJ; Palominos-Rivera, M; Perez-Sepulveda, A; Varas-Godoy, M; Venegas-Araneda, P, 2015
)
0.42
"54L/h/kg] and higher bioavailability [123%])."( Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Chmielecki, J; Chuang, BC; Guan, MY; Li, Y; Liao, M; Plesescu, M; Prakash, SR; Woo, J; Xia, CQ; Yang, JJ, 2016
)
0.43
"To evaluate the bioavailability and safety of a novel vaginal capsule containing solubilized bioidentical 17β-estradiol for vulvar and vaginal atrophy and compare its pharmacokinetics with that of an approved vaginal estradiol tablet in healthy postmenopausal women."( Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.
Amadio, JM; Bernick, BA; Mirkin, S; Pickar, JH, 2016
)
0.43
"Two randomized, single-dose, two-way cross-over, relative bioavailability trials compared the pharmacokinetics of a solubilized vaginal estradiol softgel capsule (TX-004HR, test) with that of a vaginal estradiol tablet (Vagifem®, reference) in postmenopausal women (aged 40-65 years) at 10-μg and 25-μg doses."( Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.
Amadio, JM; Bernick, BA; Mirkin, S; Pickar, JH, 2016
)
0.43
" The current results suggest that these reproductive responses may be associated with the bioavailability of EDCs in the Iguaçu River."( Vitellogenin levels and others biomarkers show evidences of endocrine disruption in fish species from Iguaçu River - Southern Brazil.
Garcia, JRE; Kupsco, A; Oliveira Ribeiro, CA; Yamamoto, FY, 2017
)
0.46
" These findings highlight the influence of carbon nanomaterials on the bioavailability of co-contaminants in organisms."( Influence of multiwall carbon nanotubes on the toxicity of 17β-estradiol in the early life stages of zebrafish.
Liu, Y; Lu, G; Sun, H; Yan, Z, 2018
)
0.48
" Bioavailability of sulfated estrogens may contribute to relief of night sweats."( SLCO1B1 genetic variation and hormone therapy in menopausal women.
de Andrade, M; Dudenkov, T; Faubion, SS; Kapoor, E; Miller, VM; Moyer, AM; Weinshilboum, RM, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Even though many food additives are poorly absorbed into systemic circulation, high concentrations could exist in the intestinal lumen, making intestinal drug transporters, such as the uptake transporter organic anion transporting polypeptide 2B1 (OATP2B1), a possible site of food additive-drug interactions."( Food Additives as Inhibitors of Intestinal Drug Transporter OATP2B1.
Deng, F; Hagström, M; Kidron, H; Koenderink, JB; Pierrot, E; Sánchez, VB; Tikkanen, A, 2020
)
0.56
"Information about the chemical constituents of SJHK were collected, and druggable compounds were screened based on oral bioavailability and drug-likeness."( Network pharmacology and molecular docking approaches to elucidate the potential compounds and targets of Saeng-Ji-Hwang-Ko for treatment of type 2 diabetes mellitus.
Ahn, D; Chung, SJ; Jeong, S; Kim, H; Kim, HH; Kim, Y; Ko, M, 2022
)
0.72
"The bioconcentration factor (BCF) is a key parameter for bioavailability assessment of environmental pollutants in regulatory frameworks."( Predicting bioconcentration factor and estrogen receptor bioactivity of bisphenol a and its analogues in adult zebrafish by directed message passing neural networks.
Chen, G; Chen, P; He, K; Shan, G; Wang, R; Yang, L; Zhu, L, 2022
)
0.72

Dosage Studied

The finding of this study shows that lower dosage of piperazinyl estrone has effect on preventing the bone losses in OVX rats, while the bone formation and the uterus are not affected. The unusual growth properties common to impeded estrogens are twofold: (a) after the threshold dosage required to initiate growth has been reached, the slope of the curve of increment of uterine weight in women is unusual.

ExcerptRelevanceReference
" Requisites of such therapy are a through history to establish a real need, a complete gynecologic examination with a Pap smear before therapy begins and annually afterward, use of the smallest daily dose of estrogen that gives the desired effect, and periodic attempts to reduce the dosage or stop the hormone."( Estrogens for the menopause. Maximizing benefits, minimizing risks.
Seller, JC, 1977
)
0.26
" The revised document should indicate the conditions under which various classes of substances constitute human health hazards -- including dosage levels and routes of entry."( Essential hormones as carcinogenic hazards.
Bowers, EJ; Clelland, RC; Hickey, RJ, 1979
)
0.26
" The results of the carcinogenic effects of these natural substances is in question because of administered dosage levels, chemical structure of the substances, the route the hormones entered the biological system, and testing done in animals and in vitro."( Essential hormones as carcinogenic hazards.
Bowers, EJ; Clelland, RC; Hickey, RJ, 1979
)
0.26
" Clinical effectiveness was directly related to dosage (2 to 8 mg/day)."( Estriol in the management of the menopause.
Aksu, MF; Greenblatt, RB; Tzingounis, VA, 1978
)
0.26
"Uterine arterial blood flow dose-response curves to systemic infusions of either estrone (E1) or estradiol-17alpha (E2alpha) were determined in ten oophorectomized, nonpregnant ewes."( Circulatory responses to systemic infusions of estrone and estradiol-17alpha in nonpregnant, oophorectomized ewes.
Rivera, R; Rosenfeld, CR, 1978
)
0.74
"A high-pressure liquid chromatographic method is described for the analysis of estrogens in pharmaceutical tablet and injectable dosage forms."( High-pressure liquid chromatographic analysis of estrogens in pharmaceuticals by measurement of their dansyl derivatives.
Roos, RW, 1978
)
0.26
" With the second divided dosage the serum oestriol levels remained uniform."( Serum oestriol, oestrone and oestradiol concentrations during oral oestriol succinate treatment in ovariectomized women.
Grönroos, M; Kaihola, HL; Punnonen, R; Rauramo, L, 1978
)
0.6
"In order to evaluate the precise role of luteinizing hormone-releasing factor (LRF) in mediating the onset of sexual behavior, the specificity, time-course, and dose-response relationship of LRF-facilitated lordosis behavior were determined."( Action of luteinizing hormone-releasing factor (lrf) in the initiation of lordosis behavior in the estrone-primed ovariectomized female rat.
McCann, SM; Moss, RL, 1975
)
0.47
"0 pigram dosage after 120 hours duration."( The glycogen-depleting effect of aqueous estrone on the cerebral hemispheres of the chick embryo.
Delphia, JM; Negulesco, JA, 1977
)
0.52
" The dosage of the drug was 750 mg."( Prostatic cancer and SCH-13521: II. Histological alterations and the pituitary gonadal axis.
Daly, JJ; Griffin, PP; Irwin, RJ; Kliman, B; MacLaughlin, RA; Prout, GR, 1975
)
0.25
" Six mature female monkeys were treated with HMG-HCG for at least 2 control ovulatory cycles at dosage levels adjusted to induced ovulation while avoiding superovulation."( The effect of indomethacin of HMG-HCG induced ovulation in the phesus monkey.
Cruz, A; Hunt, J; Stevens, VC; Wallach, EE; Wright, KH, 1975
)
0.25
"Infection of human foreskin cells (D-550) by the Snyder-Theilen strain of feline sarcoma virus produced small but countable foci and demonstrated "single-hit" dose-response kinetics."( Influence of glucocorticoid, estrogen, and androgen hormones on transformation of human cells in vitro by feline sarcoma virus.
Blakeslee, JR; Milo, GE; Olsen, RG; Schaller, JP; Yohn, DS, 1976
)
0.26
" These results confirm the dose-response relation previously established with plasma oestrogen measurements alone."( The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
Dowsett, M; Jacobs, S; Jones, AL; Lonning, PE; MacNeill, F; Powles, TJ, 1992
)
0.28
"The aim of this double blind placebo-controlled cross-over study was to evaluate the effects of fadrozole, a new oral nonsteroidal aromatase inhibitor, on basal and stimulated cortisol and aldosterone secretion at a daily dosage of 4 mg given for 14 days to eight healthy men."( The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects.
Aupetit, B; Bhatnagar, AS; Ezzet, F; Girard, F; Menard, J; Mueller, P; Trunet, PF; Zognbi, F, 1992
)
0.28
" A dose-response relationship exists for serum levels achieved after oral E2 administration."( Pharmacokinetics of oral 17 beta-estradiol.
Cassidenti, DL; Lobo, RA, 1992
)
0.28
" In view of our inability to demonstrate an effect on any parameter of endocrine function in normal and oligomenorrhoeic women, these results throw doubt on the therapeutic value of cyclofenil in its present dosage and formulation."( Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucus in normal and oligomenorrhoeic women.
Baird, DT; Beattie, G; Caird, L; Glasier, A; Hillier, H; Ledger, W; Sweeting, V; Thong, J; Yong, EL, 1992
)
0.28
" On subsequent repeated dosing with PyG, both the Km (4."( Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Coombes, RC; Dowsett, M; Griggs, LJ; Haynes, BP; Jarman, M; Jones, A; Lønning, PE; Mehta, A; Powles, T; Stein, R, 1991
)
0.28
"Forty pregnant long-tailed macaques were dosed via nasogastric intubation with 0, 25, 150, or 300 micrograms/kg of L-selenomethionine (Se) daily during organogenesis [Gestational Day (GD) 20-50]."( Developmental toxicity of L-selenomethionine in Macaca fascicularis.
Book, SA; Cukierski, MJ; Hendrickx, AG; Lasley, BL; Miller, CJ; Murphy, CJ; Tarantal, AF; Willhite, CC, 1991
)
0.28
"In order to study the effect of Toxoplasma infection on hormonal levels in pregnant ewes, twenty-eight Scottish Blackface ewes were dosed orally with Toxoplasma gondii oocytes at 91 +/- 1 days of gestation."( The effect of Toxoplasma gondii infection in unvaccinated and iscom-vaccinated pregnant ewes as monitored by plasma levels of 15-ketodihydroprostaglandin F2 alpha, progesterone, and oestrone sulphate.
Buxton, D; Edqvist, LE; Fredriksson, G; Kindahl, H; Uggla, A, 1990
)
0.47
" Doubling the dose of either drug did not enhance hormone suppression, indicating that the drug dosage is maximally suppressive."( Adrenal steroids as parameters of the bioavailability of MA and MPA.
Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990
)
0.28
"625 mg daily, combined with 1000 mg elemental calcium supplementation, was the minimum effective dosage to prevent loss of spinal bone mineral density in postmenopausal women over a 12-month period."( Effect of estrone sulfate on postmenopausal bone loss.
Baylink, DJ; Gallagher, JC; Genant, HK; Harris, ST; Herber, M; Steiger, P, 1990
)
0.68
" There was a significant monotonic dose-response relationship of estrone sulfate in raising HDL levels, lowering LDL levels, and raising the HDL/LDL ratio at all intervals measured."( Effect of cyclic estrone sulfate treatment on lipid profiles of postmenopausal women with elevated cholesterol levels.
Green, EM; Jennings, D; Katz-Karp, S; Lancaster, J; Notelovitz, M; Stoll, RW, 1990
)
0.86
" In this study, total testosterone, estrone, estradiol, and sex hormone-binding globulin were not related to prostate cancer, but plasma androstenedione showed a positive dose-response gradient."( A prospective, population-based study of androstenedione, estrogens, and prostatic cancer.
Barrett-Connor, E; Garland, C; Khaw, KT; McPhillips, JB; Wingard, DL, 1990
)
0.55
" A dose-response relation was apparent for these hormones; mean plasma levels increased concomitantly with cigarette consumption."( Cigarette smoking and levels of adrenal androgens in postmenopausal women.
Barrett-Connor, E; Khaw, KT; Tazuke, S, 1988
)
0.27
" By avoiding the first liver pass the dosage of estrogen can be halved."( Fat-soluble 17 beta-estradiol: a way of reducing dosage in steroid hormonal substitution?
Cullberg, G; Schubert, W, 1988
)
0.27
"We conducted a dose-response study in 23 postmenopausal women to compare the physiologic effects of transdermal estradiol and oral conjugated equine estrogens."( Biologic effects of transdermal estradiol.
Alkjaersig, NK; Chetkowski, RJ; Eggena, P; Fletcher, AP; Hershman, JM; Judd, HL; Lu, JK; Meldrum, DR; Randle, D; Steingold, KA, 1986
)
0.27
"40), but not for MPA and estrone, indicating better adrenal suppression by higher MPA dosage and plasma levels."( Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
Doorenbos, H; Sleijfer, DT; Sluiter, WJ; van Veelen, H; Willemse, PH, 1985
)
0.57
" It was concluded that transdermal administration of E2 at the dosage employed produces a physiological plasma protein distribution of E2 and E1 and does not affect liver protein production."( Biological and endocrine aspects of transdermal 17 beta-oestradiol administration in post-menopausal women.
Bulletti, C; Ciotti, P; Di Cosmo, D; Flamigni, C; Jasonni, VM; Lazzaretto, R; Naldi, S, 1988
)
0.27
" The oestrone sulphate terminal elimination rate constant (lambda z) was concurrently increased (mean of 46 and 79%, respectively, with the 2 dosage regimens)."( Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Kvinnsland, S; Lønning, PE; Thorsen, T; Ueland, PM, 1987
)
0.75
" In the cigarette smokers, a dose-response relationship was apparent for these hormones with mean levels increasing with increasing reported cigarette consumption."( Cigarette smoking and increased endogenous estrogen levels in men.
Barrett-Connor, E; Khaw, KT, 1987
)
0.27
" Ten patients with histologically proven endometrial hyperplasia were treated with Danazol at a dosage of 600 mg/day for 30 days."( Preliminary report on postmenopausal endometrial hyperplasia treatment with Danazol: histological and endocrinological aspects.
Bulletti, C; Ciotti, P; Flamigni, C; Jasonni, VM; La Marca, L; Naldi, S; Vignudelli, A, 1986
)
0.27
" These results provide strong evidence that a pharmacological dosage of relaxin induces an acute depression of progesterone secretion beginning within 90 min in beef heifers during late pregnancy."( Acute decrease in progesterone and increase in estrogen secretion caused by relaxin during late pregnancy in beef heifers.
Anderson, LL; Musah, AI; Schwabe, C, 1987
)
0.27
"Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1)."( Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Dowsett, M; Jeffcoate, SL; Santen, RJ; Santner, SJ; Smith, IE, 1985
)
0.27
" The results showed reduced levels of both estrogens in smokers as compared with nonsmokers in all three dosage groups."( Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause.
Christiansen, C; Jensen, J; Rødbro, P, 1985
)
0.27
" As suggested by previous studies with quinone metabolites of benzene, the catechol estrogen metabolite 2-OH estrone was significantly more potent than the parent compound at suppressing lymphocyte functions in vitro; however, dosing regimens of 2-OH estrone that suppressed blastogenic response in vivo failed to inhibit nonspecific cell-mediated growth inhibition."( Modulation of nonspecific cell-mediated growth inhibition by estrogen metabolites.
Patterson, RM; Pfeifer, RW, 1985
)
0.48
" The increase appeared to be of long duration and to have a dose-response relationship."( The stimulatory action of the prostaglandins on the production of oestrogens by the human placenta perfused in vitro.
Alsat, E; Cedard, L, 1973
)
0.25
" 5 patients participated in a dose-response tolerance study in which the drug was given over a 12-hour period at predetermined dose levels from 25-200 mcg/minute."( Hormone levels during prostaglandin F 2 infusions for therapeutic abortion.
Anderson, GG; Brock, WA; Caldwell, BV; Hobbins, JC; Speroff, L, 1972
)
0.25
" LH-FSH basal levels, prolactin, TSH, TBG, thyroxine, cortisol, and androstenedione were not changed by either dosage or duration of danazol therapy."( Danazol: endocrine and endometrial effects.
Floyd, WS, 1980
)
0.26
"Sixty postmenopausal women with climacteric symptoms were treated with either clonidine hydrochloride or piperazine estrone sulfate in two different dosage strengths."( Effect of estrogen on fasting serum cholesterol and triglyceride levels in postmenopausal women.
Varma, TR,
)
0.34
" In contradistinction to other low dosage combination oral contraceptives this new oral contraceptive has a good control of the menstrual cycle."( [Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
Huber, P; Mall-Haefeli, M; Weijers, MJ; Werner-Zodrow, I, 1982
)
0.26
" All 3 tissues produced progesterone in a significant dose-response relationship with added pregnenolone but chorion was significantly more active than the other membranes."( Local modulation of progesterone production in human fetal membranes.
Challis, J; Cruickshank, B; McLean, D; Mitchell, B, 1982
)
0.26
" Side-effects were less at the lowest dosage and were age-related."( Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983
)
0.27
" Each dosage of each formulation was ingested by three women."( Comparison of pharmacodynamic properties of various estrogen formulations.
Brenner, PF; Dozono-Takano, R; Eggena, P; Lobo, RA; Mashchak, CA; Mishell, DR; Nakamura, RM, 1982
)
0.26
" Forty-two climacteric women were studied before and after treatment with various drugs at different doses (patients receiving identical compounds served as their own controls for the evaluation of dosage effects; duration of medication: 14 days at each dose)."( Effects of various replacement oestrogens on hepatic transcortin synthesis in climacteric women.
Hammerstein, J; Moltz, L; Schneller, E; Schwartz, U; Volger, H, 1983
)
0.27
" This effect is, however, not sufficient to avoid systemic effects at the dosage used."( Effects of intravaginal oestrogen treatment upon the vaginal absorption of conjugated equine oestrogens.
Carlström, K; Furuhjelm, M; Karlgren, E; Ryd-Kjellén, E, 1982
)
0.26
"5-mg dosage of VCE raised estrone levels to values similar to those in premenopausal women in the late follicular phase, and estradiol concentrations were similar to early follicular phase concentrations."( Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women.
Eggena, P; Geola, FL; Hershman, JM; Judd, HL; Lu, JH; Mandel, FP; Meldrum, DR; Sambhi, MP, 1983
)
0.57
" The most sensitive marker was vaginal cytology, with the E2 dosage reverting the maturation index to premenopausal values."( Estrogen replacement therapy by transdermal estradiol administration.
DeFazio, JL; Eggena, P; Hershman, JM; Judd, HL; Laufer, LR; Lu, JK; Meldrum, DR; Sambhi, MP, 1983
)
0.27
" It is concluded that the effects of estrogens on the endocrine system in peri- and postmenopausal women are influenced by chemical structure, dosage and mode of administration of the estrogen as well as by the endogenous hormone profile."( Treatment with oral estrone sulphate in the female climacteric. II. Hormonal aspects.
Carlström, K; Lagrelius, A; Lunell, NO, 1981
)
0.59
"A group of 13 cows were dosed orally nine or 10 days after a normal oestrous cycle; six animals received colostrum, five animals received milk containing varying amounts of oestrone sulphate, and two cows were given milk containing a low level of oestrone sulphate."( Effects on the oestrous cycle of dairy cows of the administration of colostrum in the mid-luteal phase.
Holdsworth, RJ; Turner, CB, 1984
)
0.46
" The dosages of E3 employed appear to vary considerably, and the need was felt to establish the dosage on a scientific basis."( The significance of oestriol in the management of the post-menopause.
Aksu, MF; Greenblatt, RB; Tzingounis, VA, 1980
)
0.26
"Since unopposed estrogen therapy, as well as overly high doses, has been implicated in increasing the risk for endometrial cancer, this study tried to determine the effect of reducing the daily amount of estrogen and dividing that reduced dosage into 3 daily doses."( Pharmacokinetic studies on low dose estradiol 17 beta administered orally to postmenopausal women.
Lähteenmäki, P; Luukkainen, T; Sipinen, S, 1980
)
0.26
" These patterns allow a good diagnostic presumption before the following missing menses, which can be useful when dealing with women treated for infertility and when plasmatic dosage of hCG or beta hCG cannot be rapidly available."( [Urinary estrone and estradiol levels in the diagnostic presumption of pregnancy (author's transl)].
Chikhaoui, Y; Crastes de Paulet, A; Cristol, P; Descomps, B; Durand, G; Hedon, B; Viala, JL, 1980
)
0.68
" An alternate-day schedule with the same dosage was used for the other five patients."( Sublingual absorption of micronized 17beta-estradiol.
Brooks, P; Burnier, AM; Martin, PL; Yen, SS, 1981
)
0.26
" Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively."( Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture.
Bayard, F; Jozan, S; Kreitmann, B, 1981
)
0.5
" The oestrogen preparations available, the dosage schemes, and the modes of administration are the main aspects of therapy which will be discussed in this paper."( Oestrogen therapy in the peri-menopause: A practical approach.
Haspels, AA, 1980
)
0.26
" Long-term therapy (up to 6 months) with the 250-mg dosage showed continual suppression of estrone with no escape being observed."( In vivo effects of delta 1-testololactone on peripheral aromatization.
Barone, RM; Gambone, JC; Judd, HL; Lasley, BL; Laufer, LR; Monfort, SL, 1982
)
0.48
" Suppression of cortisol and estrogens was greater after dexamethasone (Dx) than after a glucocorticoid-equivalent dosage of prednisone (Pd)."( Loss of diurnal rhythm in plasma estrone, estradiol, and estriol in women treated with synthetic glucocorticoids at 34 to 35 weeks' gestation.
Challis, J; Patrick, J; Richardson, B; Tevaarwerk, G, 1981
)
0.54
"To study the effects of exogenous estrogens on the postmenopausal endometrium, and to determine the time course and minimum dosage of added progestins necessary to oppose estrogen stimulation, we obtained endometrial specimens from symptomatic postmenopausal women being treated with various preparations of estrogens and progestins."( Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium.
King, RJ; Pryse-Davies, J; Ryder, TA; Townsend, PT; Whitehead, MI, 1981
)
0.26
"5% suspension in the lower conjunctival sac of each eye and monkeys were dosed with the same procedure."( 17 beta-estradiol levels in blood and cerebrospinal fluid after ocular and nasal administration in women and female rhesus monkeys (Macaca mulatta).
Hahnenberger, R; Johansson, ED; Ohman, L, 1980
)
0.26
" These results indicate that 1) estrone treatment from d 30 to 45 of pregnancy and at the dosage used did not alter endometrial protein secretion or fetal survival, and 2) UHO decreased the amount of endometrial proteins available to conceptuses."( Effect of estrone treatment from day 30 to 45 of pregnancy on endometrial protein secretion and uterine capacity.
Christenson, RK; Vallet, JL, 1994
)
0.97
"This pilot study was conducted to establish the optimum oral dosage of medroxyprogesterone acetate (Provera) given daily in combination with a fixed dose of piperazine oestrone sulphate (Ogen), as hormone replacement therapy."( Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes.
Nand, SL; Webster, MA; Wren, BG, 1995
)
0.77
" There was an indication that complete suppression of oestradiol and oestrone was not maintained throughout the 12-h dosing period, but the data and its interpretation are complicated by a minor diurnal rhythm in these parameters."( Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.
Coombes, RC; Dowsett, M; Moore, J; Powles, TJ; Rubens, R; Smith, IE; Smithers, D; Trunet, PF, 1994
)
0.52
" Nafarelin 200 mcg daily significantly reduced signs and symptoms of endometriosis, although five patients needed a dosage increase before menses stopped."( Low dose intranasal nafarelin for the treatment of endometriosis.
Bullingham, RE; Harris, SR; Jacobson, J, 1994
)
0.29
" Following priming with estrone, ovariectomized rats were treated with estrone plus progesterone, progesterone alone, or progesterone plus various dosage levels of MXC."( Replacement of estrogen by methoxychlor in the artificially-induced decidual cell response in the rat.
Cummings, AM, 1993
)
0.59
" At the single dosage administered, estrone and estradiol produced all females at a male-producing incubation temperature."( The relative effectiveness of androstenedione, testosterone, and estrone, precursors to estradiol, in sex reversal in the red-eared slider (Trachemys scripta), a turtle with temperature-dependent sex determination.
Bergeron, JM; Cantú, AR; Crews, D; Rhen, T, 1995
)
0.8
" Volunteers in the first trial were dosed with 3 mg of ZD1033 daily over 10 days to assess the effects on endocrinology of ZD1033 and establish a pharmacokinetic profile."( Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
Dowsett, M; Fisher, GV; Selen, A; Wyld, PJ; Yates, RA, 1996
)
0.29
" This study demonstrates that, in the red-eared slider, there is a complex interaction between incubation temperature, different estrogens, and the dosage effect of each hormone."( The relative effectiveness of estrone, estradiol-17 beta, and estriol in sex reversal in the red-eared slider (Trachemys scripta), a turtle with temperature-dependent sex determination.
Cantú, AR; Crews, D; Rhen, T; Vohra, R, 1996
)
0.58
" Dose-response analysis indicated an IC50 of 350 nM for (p-O-sulfamoyl)-N-tetradecanoyl tyramine for the inhibition of MDA-MB-231 estrone sulfatase activity."( Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
Hegde, PV; Li, PK; Selcer, KW, 1997
)
0.86
" Estrone levels did not vary with route of administration but correlated with the dosage administered."( Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol.
Bates, GW; Blauer, KL; Hansen, M; Lobo, R; Price, TM; Stanczyk, F, 1997
)
1.21
" In the present study, pretreatment of male Swiss Webster mice with increasing doses of fenitrothion resulted in dose-dependent biphasic decreases in 2-OHE2 and 4-OHE2 production in mouse hepatic microsomes compared to control, with substantial decreases even at a dosage as low as 7 mg/kg."( The effects of the phosphorothioate insecticide fenitrothion on mammalian cytochrome P450-dependent metabolism of estradiol.
Berger, CW; Sultatos, LG, 1997
)
0.3
" The serum levels of estradiol, free and conjugated estrone were measured until 48 h after an oral dosage of 4 mg estradiol valerate (CAS 979-32-8)."( Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women.
Börner, A; Breitbarth, H; Koytchev, R; Mayer, O; Mellinger, U; Zimmermann, H, 1998
)
0.55
"05 mg/day dosage of 17 beta-estradiol via a skin patch and the remaining six wore a placebo skin patch."( Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
Asthana, S; Baker, LD; Birnbaum, RS; Craft, S; Lofgreen, CP; Plymate, SR; Raskind, MA; Veith, RC, 1999
)
0.3
" We dosed intact male Wistar rats from postnatal day (PND) 23 to 53 and examined several reproductive endpoints."( The effect of atrazine on puberty in male wistar rats: an evaluation in the protocol for the assessment of pubertal development and thyroid function.
Cooper, RL; Guidici, DL; Laws, SC; Stoker, TE, 2000
)
0.31
" This difference may be attributed to the higher dosage of oral E2 that is required because of the low bioavailability compared with the transdermal dosages."( Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women.
Hodis, HN; Mack, WJ; Paulson, RJ; Shoupe, D; Slater, CC; Stanczyk, FZ,
)
0.43
" 16alpha-OHE(1) increased uterine weight in a dose-response manner to values that did not differ from rats treated with E(2)."( Tissue-selective effects of continuous release of 2-hydroxyestrone and 16alpha-hydroxyestrone on bone, uterus and mammary gland in ovariectomized growing rats.
Lotinun, S; Turner, RT; Westerlind, KC, 2001
)
0.55
"This study compares the pharmacokinetic performance of a matrix system for transdermal 17-beta-estradiol (E(2)) delivery using multiple consecutive dosing with a first application in postmenopausal women undergoing hormone replacement therapy."( 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: experimental results.
Rohr, UD; Saeger-Lorenz, K, 2002
)
0.31
" These variations depend on the different methods of dosage and on individual variations among patients."( [What happens in our patients' bodies to the steroid hormones we prescribe? Pt. 1. Estrogens].
Rozenbaum, H, 1981
)
0.26
" Changing the capture antigen markedly influenced the dose-response lines."( Factors influencing the measurement of oestrone sulphate by dipstick particle capture immunoassay.
Henderson, K; Stewart, J, 2002
)
0.58
" The D-ring metabolites did not show such clear biphasic patterns, in most of them the stimulatory effect prevailed at the highest dosage used."( The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells.
Lippert, C; Mueck, AO; Seeger, H, 2003
)
0.32
"The finding of this study shows that lower dosage of piperazinyl estrone has effect on preventing the bone losses in OVX rats, while the bone formation and the uterus are not affected, thus supporting the hypothesis that piperazinyl estrone has the potential to prevent postmenopausal bone loss in women with less side effects."( [Piperazinyl estrone prevents bone loss in ovariectomized rats].
Chen, HQ; Hu, B; Huang, LF; Li, QN; Weng, LL; Zheng, H, 2003
)
0.93
" One ring designated as PI-002 (n = 8) delivered in vitro estradiol 160 microg/day and progesterone 20 mg/day, while the other (PI-003; n = 12) delivered the same dosage of estradiol but only half the progesterone (10 mg/day)."( Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women.
Hamada, AL; Johansson, E; Maruo, T; Nash, H; Samoto, T; Spitz, IM; Yoshida, S, 2003
)
0.32
" A preliminary dose-response study performed in weanling rats determined 2000 microg/kg/day to be the optimal dose of 16alpha-OHE(1) for studying estrogenic effect on bone."( Comparative effects of long-term continuous release of 16 alpha-hydroxyestrone and 17 beta-estradiol on bone, uterus, and serum cholesterol in ovariectomized adult rats.
Kennedy, AM; Lotinun, S; Turner, RT; Westerlind, KC, 2003
)
0.55
" The unusual growth properties common to impeded estrogens are twofold: (a) after the threshold dosage required to initiate growth has been reached, the slope of the curve of increment of uterine weight in response to increased steroid dosage is very gradual rather than steep; (b) these compounds possess the ability to inhibit to a limited extent the uterine growth induced by estrone administered concurrently."( The depression of estrone-induced uterine growth by phenolic estrogens with oxygenated functions at positions 6 or 16: the impeded estrogens.
HUGGINS, C; JENSEN, EV, 1955
)
0.74
" The dose-response curve of the latter did not parallel that of E1G and is a possible cause of the non-parallelism."( Statistical correction for non-parallelism in a urinary enzyme immunoassay.
Brindle, E; Campbell, KL; Handcock, MS; Klein, NA; Mar, C; Miller, RC; O'Connor, KA; Shofer, JB; Soules, MR, 2004
)
0.32
" The findings of this study show that piperazinyl estrone at dosage of 1 mg/kg/d is most efficacious in preventing the bone losses in aged rats and has no side effect on uterus."( [Piperazinyl estrone, a new estrogen derivant, prevents bone loss in aged rats].
Li, Q; Weng, L; Wu, X; Zheng, H, 2005
)
0.95
"Our recent study showed a dose-response relationship between environmental tobacco smoke (ETS) and the risk of early pregnancy loss."( Effect of environmental tobacco smoke on levels of urinary hormone markers.
Chen, C; Lasley, B; Overstreet, JW; Ryan, L; Stanford, JB; Tang, G; Wang, L; Wang, X; Xing, H; Xu, X; Yang, F, 2005
)
0.33
" A dose-response relationship in the inhibitory effect of this compound further confirmed the validity of the model for testing the drug candidates in vivo."( Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme.
Huhtinen, K; Husen, B; Kangas, L; Messinger, J; Poutanen, M; Thole, H, 2006
)
0.33
" STX64 was administered orally (nine patients at 5 mg and five patients at 20 mg) as an initial dose followed 1 week later by 3 x 2 weekly cycles, with each cycle comprising daily dosing for 5 days followed by 9 days off treatment."( Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Coombes, RC; Dobbs, N; Elliott, M; Kulinskaya, E; Potter, BV; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Sufi, S; Vigushin, D; Ward, R; Wilson, RH; Woo, LW, 2006
)
0.33
"The median inhibition of STS activity by STX64 was 98% in peripheral blood lymphocytes (PBL) and 99% in breast tumor tissue at the end of the 5-day dosing period."( Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Coombes, RC; Dobbs, N; Elliott, M; Kulinskaya, E; Potter, BV; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Sufi, S; Vigushin, D; Ward, R; Wilson, RH; Woo, LW, 2006
)
0.33
" The dose-response relationship revealed two vastly different affinities (EC(50(high-affinity))=4."( Agonist specific L-type Ca(2+)-current stimulation in ventricular myocytes by a novel steroid-like compound.
Egger, M; Keller, M; Niggli, E; Pignier, C; Santelli, M; Vacher, B, 2006
)
0.33
" Dose-response studies in the same rat model demonstrated that more than 90% inhibition of STS activity in tumors was necessary to induce tumor shrinkage."( A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models.
Akinaga, S; Anazawa, H; Ishida, H; Kuwabara, T; Li, PK; Murakata, C; Nakata, T; Sato, N; Shiotsu, Y; Suzuki, M; Takebayashi, M; Tanaka, H; Terasaki, Y, 2007
)
0.34
" After an overnight fast, euglycemic-hyperinsulinemic clamp studies were performed 2 hours after single oral dosing as follows: (1) A-348441 at 100 mg/kg or (2) vehicle."( Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance.
Jacobson, P; Mika, A; Nguyen, P; Ohman, L; Opgenorth, T; von Geldern, TW; Wilcox, D; Zinker, B, 2007
)
0.34
" Sprague-Dawley rats were gavaged for 14 days with DBA (0-150mg/kg) and ovariectomized on dosing day 11, and at the same time implanted with an estradiol capsule to generate daily LH surges."( Moderating influence of the drinking water disinfection by-product dibromoacetic acid on a dithiocarbamate-induced suppression of the luteinizing hormone surge in female rats.
Buckalew, AR; Cooper, RL; Ferrell, JM; Goldman, JM; Murr, AS, 2007
)
0.34
" Levels of disulfated metabolites in serum and tissues were higher (3- to 5-fold) after multiple dosing than after a single dose."( Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate.
Blok, LJ; Burger, CW; Hanifi-Moghaddam, P; Kloosterboer, HJ; Verheul, HA, 2007
)
0.52
" Dose-response patterns were frequently nonmonotonic."( Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation.
Jeng, YJ; Kochukov, MY; Watson, CS, 2008
)
0.6
"1% offers multiple dosing options to individualize patient therapy, including the lowest available effective dose (0."( Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Ackerman, RT; Halvorsen, MB; Hedrick, RE; Koltun, WD; Lambrecht, LJ,
)
0.13
" Previous concomitant dosing studies in rats using rifamycin SV, a general organic anion-transporting polypeptide (OATP) inhibitor, suggested that the high oral absorption of azithromycin and clarithromycin may be caused by facilitative uptake by intestinal Oatps."( Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.
Davis, CB; Dawson, PA; Garver, E; Han, C; Haywood, J; Lan, T; Rao, A, 2009
)
0.35
" Several analogs were evaluated for metabolic stability in human liver microsomes and in vivo in a rat cassette dosing model."( Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
Agoston, GE; Hunsucker, K; LaVallee, TM; Pribluda, V; Shah, JH; Suwandi, L; Swartz, GM; Treston, AM; Zhan, XH, 2009
)
0.63
"Fifty-eight women received either 10 microg or 25 microg estradiol vaginal tablets, administered once daily for 2 weeks, followed by twice-weekly dosing for 10 weeks."( Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
Eugster-Hausmann, M; Lehnick, D; Waitzinger, J, 2010
)
0.36
" Blood samples were obtained before and after dosing at designated times."( Pharmacokinetics of a modified-release estrogen tablet.
Bhamra, R; Kaercher, U; Oleary, CM,
)
0.13
"Blood samples were collected 48 hours before initial dosing for baseline levels and at multiple occasions during the study until 48 hours after final study dosing (day 29)."( A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream.
Bhamra, RK; DiLiberti, CE; Hendy, CH; Jenkins, RG; Liu, JH; Margolis, MB, 2011
)
0.37
" Continuous flow biofilm reactors were operated with two different nutrient media under dosage of estradiol and ethinylestradiol."( Investigation on the removal of natural and synthetic estrogens using biofilms in continuous flow biofilm reactors and batch experiments analysed by gas chromatography/mass spectrometry.
Pieper, C; Rotard, W, 2011
)
0.37
" Blood samples were collected scheduled intervals for 24 hours after the last dosing to determine plasma concentrations of atorvastatin acid, atorvastatin lactone, 2-hydroxy atorvastatin acid, and 2-hydroxy atorvastatin lactone."( The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Cho, JY; Jang, IJ; Kim, SE; Kim, TE; Lee, MG; Shin, KH; Shin, SG; Song, IS; Yoon, SH; Yu, KS, 2011
)
0.37
"Substances that compete for the same saturable intestinal transporters may when dosed together lead to altered permeability and hence influence bioavailability."( Simulating kinetic parameters in transporter mediated permeability across Caco-2 cells. A case study of estrone-3-sulfate.
Rapin, N; Rolsted, K; Steffansen, B, 2011
)
0.58
" These findings indicate that the influence of smoking upon the metabolism of estrogen therapy is constant and without dose-response for standard smoking intensities."( Acute and long-term estradiol kinetics in smoking postmenopausal women.
Bjarnason, NH; Christiansen, C; Jørgensen, HL, 2012
)
0.38
"Our objective was to assess metabolic effects of oral vs transdermal (TD) 17β-E₂ replacement using estrogen concentration-based dosing in girls with Turner syndrome (TS)."( Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndrome.
Hossain, J; Klein, KO; Mauras, N; Mericq, V; Ross, JL; Santen, RJ; Singh, R; Taboada, M; Torres-Santiago, L; Unanue, N, 2013
)
0.39
" High dosage of H2O2 and low pH were favorable for the degradation of EDCs."( Removal of phenolic endocrine disrupting compounds from waste activated sludge using UV, H2O2, and UV/H2O2 oxidation processes: effects of reaction conditions and sludge matrix.
Li, Y; Zhang, A, 2014
)
0.4
" The effect of earlier optimized ultrasonication dosage on the anaerobic digestion of E1 and E2 was also characterized."( Anaerobic digestibility of estrogens in wastewater sludge: effect of ultrasonic pretreatment.
Ali, S; Chawla, C; Nakhla, G; Ray, MB; Rehmann, L; Sarkar, S, 2014
)
0.4
" Effects of initial pH and CaO2 dosage were investigated."( Performance of calcium peroxide for removal of endocrine-disrupting compounds in waste activated sludge and promotion of sludge solubilization.
Li, Y; Wang, J; Zhang, A, 2015
)
0.42
"The remediation of four estrogenic endocrine-disrupting compounds (EDCs), estrone (E1), estradiol (E2), ethinylestradiol (EE2) and estriol (E3), was measured in saturated and unsaturated carbonate sand-filled columns dosed with wastewater from a sewage treatment plant."( Behaviour of estrogenic endocrine-disrupting chemicals in permeable carbonate sands.
Erler, DV; Eyre, BD; Kimber, S; Shepherd, BO; Tait, DR; van Zwieten, L, 2015
)
0.65
" Postmenopausal women (aged 40-65 y) were randomly assigned to one of three dosing sequences of test and reference products (TRR, RTR, or RRT, where T is the test drug and R is the coadministered reference product), with each of the three periods separated by a 14-day washout."( Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy.
Amadio, JM; Bernick, B; Bon, C; Mirkin, S; Pickar, JH, 2015
)
0.42
" Blood samples were obtained for PK analysis, and concentrations of NOMAC, E2 and its metabolite estrone (E1) were determined for up to 129h following dosing to obtain PK data."( Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.
de Greef, R; Gerrits, M; Kerbusch, T; Post, TM, 2016
)
0.65
" Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-475 was hydrolyzed to M-I during the absorption process and the concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration to rats."( Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.
Asahi, S; Ebihara, T; Kondo, T; Moriwaki, T; Moriya, Y; Tagawa, Y; Takeuchi, T, 2016
)
0.43
" Modeling results suggest that for E1, E2 and EE2, AOB-linked biodegradation is dominant over biodegradation by HB at all investigated COD dosing levels."( Model-based assessment of estrogen removal by nitrifying activated sludge.
Dai, X; Liu, Y; Ni, BJ; Peng, L; Song, S; Sun, J, 2018
)
0.48
" With free available chlorine concentrations (FAC) in the UV chamber influent of at least 5 mg/L (11 mg/L of dosed Cl₂), the total estrogenic activity could be reduced by at least 97%."( Removal of Emerging Contaminants and Estrogenic Activity from Wastewater Treatment Plant Effluent with UV/Chlorine and UV/H₂O₂ Advanced Oxidation Treatment at Pilot Scale.
Kuch, B; Kugele, A; Lange, C; Minke, R; Richter, P; Rott, E, 2018
)
0.48
" SD rats administrated with different dosage of NP every other day for 28d."( Effects of nonylphenol administration on serum, liver and testis estrogen metabolism.
Bu, L; Guo, Y; Huang, Q; Huang, S; Liu, C; Yang, J; Yang, T; Yang, Y, 2019
)
0.51
" PBK models were developed using a generic approach and in vitro concentration-response data from the MCF-7 proliferation assay and the yeast estrogen screening assay were translated into in vivo dose-response data."( Development of a Generic Physiologically Based Kinetic Model to Predict In Vivo Uterotrophic Responses Induced by Estrogenic Chemicals in Rats Based on In Vitro Bioassays.
Rietjens, IMCM; van Ravenzwaay, B; Zhang, M, 2020
)
0.56
" Results showed no observable reduction of carbamazepine by either anaerobic or aerobic biofilms over a dosing period of 51-days followed by an additional 23 days of observation."( Anaerobic-aerobic biofilm-based digestion of chemical contaminants of emerging concern (CEC) and pathogen indicator organisms in synthetic wastewater.
Babcock, RW; Cooney, MJ; Kirs, M; Lamichhane, KM; Lin, S; Rong, K, 2020
)
0.56
" Multidaily dosing may be necessary to suppress testosterone levels with sublingual E2."( Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women.
Doll, E; Gunsolus, I; Lamberton, N; Sarvaideo, JL; Tangpricha, V; Thorgerson, A, 2022
)
0.72
" We also conducted a dose-response meta-analysis of prospective studies of circulating estrone and estradiol with colorectal, colon, and rectal cancer risk in postmenopausal women."( Endogenous Circulating Sex Hormone Concentrations and Colon Cancer Risk in Postmenopausal Women: A Prospective Study and Meta-Analysis.
Ardanaz, E; Aune, D; Bueno-de-Mesquita, B; Colorado-Yohar, SM; Cross, AJ; Dimou, N; Fortner, RT; Fournier, A; Gicquiau, A; Gram, IT; Gunter, MJ; Harbs, J; Harlid, S; Jakszyn, P; Kaaks, R; Keski-Rahkonen, P; Krogh, V; Kvaskoff, M; Masala, G; Mori, N; Murphy, N; Panico, S; Rinaldi, S; Sacerdote, C; Sánchez, MJ; Schulze, MB; Severi, G; Travis, R; Tsilidis, KK; Tumino, R; Van Guelpen, B; Waaseth, M; Watts, EL, 2021
)
0.84
" Optimization of the preparation process considered factors like molar Mg/Fe ratio, CKD dosage, pH, and SDS dosage using Response Surface Methodology (RSM)."( Preparation of coated MgFe layered double hydroxide nanoparticles on cement kiln dust and intercalated with sodium dodecyl sulfate as an intermediate layer for the adsorption of estrogen from water.
Abdul-Kareem, MB; Al-Ansari, N; Faisal, AAH; Hassan, WH; Hatshan, MR; Lakhera, SK; Rashid, HM, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
estrogenA hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
phenolic steroid
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (25)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Metabolism of steroid hormones2537
Estrogen biosynthesis612
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Endogenous sterols1838
Phase II - Conjugation of compounds73122
Cytosolic sulfonation of small molecules1747
Sulfate/Sulfite Metabolism620
Androgen and Estrogen Metabolism1230
17-beta Hydroxysteroid Dehydrogenase III Deficiency1230
Sulfite Oxidase Deficiency620
Aromatase Deficiency1230
Androstenedione Metabolism1823
Estrone Metabolism1622
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Male steroid hormones in cardiomyocyte energy metabolism1119
Sulfatase and aromatase pathway1414
estradiol biosynthesis I59
estradiol biosynthesis I (via estrone)29
Biochemical pathways: part I0466
Estrogen metabolism025

Protein Targets (80)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency6.30960.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency6.30960.025120.237639.8107AID886
endonuclease IVEscherichia coliPotency31.62280.707912.432431.6228AID1708
RAR-related orphan receptor gammaMus musculus (house mouse)Potency17.56480.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency29.09290.004110.890331.5287AID504467
NFKB1 protein, partialHomo sapiens (human)Potency3.98110.02827.055915.8489AID895; AID928
GALC proteinHomo sapiens (human)Potency0.631028.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency17.58860.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency3.58940.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency7.66960.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588516; AID743035; AID743036; AID743040; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency0.01930.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency14.25460.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency0.30300.000417.946075.1148AID1346795
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency4.46680.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.72830.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency5.71780.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency37.07840.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency7.09800.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency20.68200.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.45260.000229.305416,493.5996AID1259383; AID588514; AID743069; AID743075; AID743077
GVesicular stomatitis virusPotency4.11970.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency34.70780.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency10.68220.023723.228263.5986AID743223
arylsulfatase AHomo sapiens (human)Potency0.95281.069113.955137.9330AID720538
activating transcription factor 6Homo sapiens (human)Potency0.13800.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.098819.739145.978464.9432AID1159509
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.19950.540617.639296.1227AID2364; AID2528
hexokinase-4 isoform 1Homo sapiens (human)Potency39.81072.511913.800328.1838AID743207
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency2.685523.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency100.00003.548119.542744.6684AID743266
glucokinase regulatory proteinHomo sapiens (human)Potency39.81072.511913.800328.1838AID743207
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency15.84890.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.99530.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency14.09750.891312.067628.1838AID1459; AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency112.20206.309660.2008112.2020AID720707
Interferon betaHomo sapiens (human)Potency4.11970.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency4.11970.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency3.54811.000010.475628.1838AID1457
TAR DNA-binding protein 43Homo sapiens (human)Potency4.46681.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency4.11970.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.99531.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency4.11970.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.12610.00000.723732.7000AID1797922; AID1797995; AID262950; AID467824; AID625258; AID70200
Estrogen receptorHomo sapiens (human)Ki0.00220.00000.42297.9070AID625258
Corticosteroid-binding globulinHomo sapiens (human)Ki10.00000.01323.248110.0000AID51055
Steryl-sulfataseHomo sapiens (human)IC50 (µMol)51.00000.00010.40717.6000AID623102
AromataseHomo sapiens (human)Ki2.50000.00000.60469.5010AID1270809
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)6.58900.11003.26419.0330AID625146
17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)IC50 (µMol)0.41340.00751.36125.5000AID260452; AID320275; AID396110; AID396111; AID467823
17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)Ki4.75150.00304.75159.5000AID396108; AID711551
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)11.61700.00101.979414.1600AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki7.74500.00031.21858.9270AID625228
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)5.30100.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki2.81600.00000.70488.1930AID625222
Alpha-synucleinHomo sapiens (human)IC50 (µMol)93.10000.19003.82049.8000AID1695728
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)13.63000.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki8.67600.00030.769310.0000AID625217
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Ki15.70001.10004.51259.8000AID681147
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)50.00000.00130.86969.9000AID1337729
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.37430.00010.529432.7000AID1797922; AID1797995; AID1797996; AID262948; AID70515
Ghrelin O-acyltransferaseHomo sapiens (human)IC50 (µMol)1,000.00006.00007.50008.0000AID1802486
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)6.50000.00401.966610.0000AID678802; AID678803
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)EC50 (µMol)0.11000.00000.53054.4000AID1724578; AID1724579; AID440681; AID70185; AID70186; AID70191
Sex hormone-binding globulinHomo sapiens (human)Kd0.00660.00020.34964.7863AID318680
Mu-type opioid receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00700.00000.06470.9320AID440681
Mu-type opioid receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.00800.00000.04930.9320AID440682
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)0.16320.00000.47954.8900AID1724577; AID1724580; AID1724581; AID262953; AID262955; AID440682; AID70504; AID70505; AID70507
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)ED500.05100.05101.32552.6000AID70192
17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)Km4.60004.60004.60004.6000AID320283
Estrogen receptor betaHomo sapiens (human)ED500.07000.07001.88503.7000AID70508
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (367)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
glucocorticoid metabolic processCorticosteroid-binding globulinHomo sapiens (human)
negative regulation of endopeptidase activityCorticosteroid-binding globulinHomo sapiens (human)
steroid catabolic processSteryl-sulfataseHomo sapiens (human)
female pregnancySteryl-sulfataseHomo sapiens (human)
epidermis developmentSteryl-sulfataseHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
steroid biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estrogen biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
lysosome organization17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
skeletal muscle tissue development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estrogen metabolic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
gene expression17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
bone development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
adipose tissue development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cellular response to metal ion17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
peptide hormone processingGhrelin O-acyltransferaseHomo sapiens (human)
peptidyl-serine octanoylationGhrelin O-acyltransferaseHomo sapiens (human)
lipid modificationGhrelin O-acyltransferaseHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (140)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingCorticosteroid-binding globulinHomo sapiens (human)
serine-type endopeptidase inhibitor activityCorticosteroid-binding globulinHomo sapiens (human)
steryl-sulfatase activitySteryl-sulfataseHomo sapiens (human)
sulfuric ester hydrolase activitySteryl-sulfataseHomo sapiens (human)
metal ion bindingSteryl-sulfataseHomo sapiens (human)
arylsulfatase activitySteryl-sulfataseHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
catalytic activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
steroid binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
small molecule binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein homodimerization activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
NADP binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
NADP+ binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estradiol binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
O-acyltransferase activityGhrelin O-acyltransferaseHomo sapiens (human)
acyltransferase activity, transferring groups other than amino-acyl groupsGhrelin O-acyltransferaseHomo sapiens (human)
serine O-acyltransferase activityGhrelin O-acyltransferaseHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (72)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
extracellular regionCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular exosomeCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
lysosomeSteryl-sulfataseHomo sapiens (human)
endosomeSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulumSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulum lumenSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulum membraneSteryl-sulfataseHomo sapiens (human)
Golgi apparatusSteryl-sulfataseHomo sapiens (human)
plasma membraneSteryl-sulfataseHomo sapiens (human)
membraneSteryl-sulfataseHomo sapiens (human)
intracellular membrane-bounded organelleSteryl-sulfataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
cytoplasm17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cytosol17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cytosol17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
endoplasmic reticulumGhrelin O-acyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneGhrelin O-acyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneGhrelin O-acyltransferaseHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (298)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID192040Weight of rat femur ash tested after intramuscular administration of 18 ug/kg of compound when compared to vehicle2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID112883Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 0.2 ug1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities, and mammary tumor inhibiting activity.
AID291685Effect on femur length in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID130416Antiestrogenic activity in uterotrophic test in mice at 0.1 ug1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID284771Inhibition of 17beta-HSD1 over-expressed in intact T47D cells at 0.1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID320272Inhibition of 17beta-HSD1 in human T47D cells assessed as inhibition of transformation of [14C]-estrone into [14C]estrogen at 0.1 uM after 24 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1695728Inhibition of alpha-synuclein aggregation (unknown origin) incubated for 8 days by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID681343TP_TRANSPORTER: inhibition of topotecan uptake in BCRP-expressing K562 cells2003Molecular cancer therapeutics, Jan, Volume: 2, Issue:1
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
AID284770Inhibition of 17beta-HSD1 over-expressed in intact T47D cells at 1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID113069Uterotrophic effect in mice at 0.4 ug1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydr
AID588994Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, BCRP2010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID130419Antiestrogenic activity in uterotrophic test in mice at 0.1 ug1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
AID440681Activity at human recombinant ERalpha by fluorescence polarization assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID681612TP_TRANSPORTER: transepithelial transport in MDR1-expressing MDCK cells2004Pharmaceutical research, Jul, Volume: 21, Issue:7
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
AID690786Induction of ERalpha degradation in human MCF7 cells at 30 uM after 24 hrs by Western blot analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.
AID55148The compound was tested in vitro for its ability to initiate DNA replication1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Effect of steroids on DNA synthesis in an in vitro replication system: initial quantitative structure-activity relationship studies and construction of a non-estrogen receptor pharmacophore.
AID70185Ability to activate estrogen receptor 1-mediated transcription.2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists.
AID262948Displacement of [3H]estrone from ER beta2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID69541Relative binding affinity against Estrogen receptor as inhibition of [3H]estradiol binding in rat uterus1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Selenium labeling in nuclear medicine. 2. D ring substituted estrogens.
AID291688Effect on mineral content in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID424701Toxicity in ovariectomized ICR mouse assessed as tail bleeding time at 110.3 nmol/kg, po for 90 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID680986TP_TRANSPORTER: inhibition of Topotecan efflux (Topotecan: 20 uM, Estrone: 100 uM) in BCRP-expressing K562 cells: flow cytometric analysis2002Japanese journal of cancer research : Gann, Mar, Volume: 93, Issue:3
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
AID140438Uterotrophic effect in mice as uterine weight(mg) relative to body weight(g) at 0.4 ug dose1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
6-Alkyl-12-formylindolo[2,1-a]isoquinolines. Syntheses, estrogen receptor binding affinities, and stereospecific cytostatic activity.
AID171531Percentage content of calcium in femur tested in the compound using male ICR rats when compared to vehicle2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID112886Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 1 ug1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities, and mammary tumor inhibiting activity.
AID212920Binding affinity against transport protein testosterone binding globulin.1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID262952Selectivity for ER beta over ER alpha2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID1594584Displacement of fluormone tracer from full length human recombinant ERbeta incubated for 2 hrs by competitive fluorescence polarization binding assay relative to estradiol2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID320283Activity of 17beta-HSD12008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
AID91607Relative stimulation of alkaline phosphatase (AlkP) activity in Ishikawa cells2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Estradiol-16alpha-carboxylic acid esters as locally active estrogens.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID284769Inhibition of 17beta-HSD1 over-expressed in intact T47D cells at 10 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID284774Inhibition of 17beta-HSD12 over-expressed in intact HEK293 cells at 10 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID70507Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor beta.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID103554Growth response in cultures of MCF-7 (human breast cancer cell line) cells1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
AID70504Ability to activate estrogen receptor 2-mediated transcription.2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists.
AID680756TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.04 uM, #Estrone: 100 uM) in OATP-C-expressing HEK293 cells2001Pharmaceutical research, Sep, Volume: 18, Issue:9
Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C.
AID192044Weight of rat femur tested after intramuscular administration of 18 ug/kg of compound when compared to vehicle2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID69682Binding affinity against Estrogen receptor with relative to E22003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens.
AID168222Activity of alkaline phosphatase (ALP) tested in serum of rat when 18 ug/kg of compound was administered intramuscularly2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID130564Anti-uterotrophic effect in mice at 0.1 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxyphenyl)ethane estrogens and antiestrogens.
AID192036Weight of rat body tested after intramuscular administration of 18 ug/kg of compound when compared to vehicle2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID291691Effect on spleen weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID1724581Agonist activity at full length human ERbeta receptor assessed as transcriptional activity incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID284768Inhibition of 17beta-HSD1 over-expressed in intact HEK293 cells at 0.1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID113032Uterotrophic effect in mice at 0.4 ug dose(Expt 1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID623102Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate after 10 mins by fluorescence assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives.
AID137108Uterotrophic effect in mice on simultaneous administration with 0.4 ug estrogen1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
1-(aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists.
AID71138Ratio of displacement of 17-beta-[3H]-estradiol from calf uterine estrogen receptor compared to 17-beta-estradiol after 20 hr incubation in 7%DMF1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
AID187204Percentage content of phosphor in femur tested in the compound using male ICR rats2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID291680Effect on serum ALP lavel in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID291683Effect on dry weight of femurs in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID112898Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 6)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID1069338Inhibition of VGLUT in rat brain assessed as [3H]-L-Glu uptake into synaptic vesicles at 250 uM relative to control2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroids.
AID1313659Binding affinity to human 17-beta-HSD14 assessed as change in melting temperature at 0.25 mM by thermal shift assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
New Insights into Human 17β-Hydroxysteroid Dehydrogenase Type 14: First Crystal Structures in Complex with a Steroidal Ligand and with a Potent Nonsteroidal Inhibitor.
AID681587TP_TRANSPORTER: drug resistance (Mitoxantrone) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID678965TP_TRANSPORTER: drug resistance in BCRP-expressing PA317 cells2003International journal of cancer, Dec-10, Volume: 107, Issue:5
Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
AID320275Inhibition of 17beta-HSD1 in human T47D cells assessed as inhibition of transformation of [14C]-estrone into [14C]estrogen2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID70505Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID320273Inhibition of 17beta-HSD1 in human T47D cells assessed as inhibition of transformation of [14C]-estrone into [14C]-estrogen at 1 uM after 24 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
AID260450Inhibition of 17-beta HSD1 in T47D cells at 10 uM2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
AID467824Displacement of [3H]17beta-estradiol from human ERalpha expressed in SF9 cells2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
AID70192Affinity of compound towards human estrogen receptor alpha2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase.
AID137257Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 15.2+/-2.9)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID424688Antiosteoporosis activity against ovariectomized ICR mouse assessed as serum ALP activity at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID260452Inhibition of 17-beta HSD1 in T47D cells2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
AID130736Estrogenic activity in uterotrophic test in mice at 0.4 ug1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
AID137127Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 14.6+/-2.7)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID130599Estrogenic activity in uterotrophic test in mice at 0.4 ug1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
AID51058Binding affinity towards corticosteroid-binding globulin (CBG)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID711551Inhibition of human estradiol 17beta-dehydrogenase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID112872Antiuterotrophic activity in mice at 0.1 ug dose1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Mammary tumor inhibiting effect of 3,3'-diacetoxy-alpha, beta-dialkylstilbenes and of related stilbene oxides.
AID467825Inhibition of His-tagged human 17beta-HSD1 expressed in Escherichia coli at 2 uM by scintillation counting2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
AID678803TP_TRANSPORTER: drug resistance(Mitoxantrone) in BCRP-expressing K562 cells2003Molecular cancer therapeutics, Jan, Volume: 2, Issue:1
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
AID69381Compound was evaluated in vivo for estrogenic receptor potency relative to ethynylestradiol in rat. 1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID424700Toxicity in ovariectomized ICR mouse assessed as tail bleeding time at 110.3 nmol/kg, po for 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID70515Binding affinity towards estrogen receptor beta by [3H]17-beta-estradiol displacement.2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists.
AID51056Binding affinity to the corticosteroid-binding globulin (CBG) receptor.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID195399Fold induction as increase in BrdU labeling index over estrone treatment alone in lobular-aveolar rat mammary buds by progestin treatment1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID68899Estrogen receptor (ER) binding affinity1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study.
AID1504637Inhibition of recombinant human CYP1B1 expressed in supersomes coexpressing P450 reductase at 0.3 uM using 7-ethyl-O-resorufin as substrate after 45 mins in presence of NADPH by fluorescence assay relative to control2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Structure-Based Design and Synthesis of New Estrane-Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors.
AID681156TP_TRANSPORTER: drug resistance (SN-38) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID113034Uterotrophic effect in mice at 0.4 ug dose(Expt 4)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID262953Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID424686Antiosteoporosis activity against ovariectomized ICR mouse assessed as serum calcium level at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1594583Displacement of fluormone tracer from full length human recombinant ERalpha incubated for 2 hrs by competitive fluorescence polarization binding assay relative to estradiol2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Synthesis and characterization of hydrogen peroxide activated estrogen receptor beta ligands.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID291686Effect on calcium level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID291690Effect on liver weight in ovariectomized mouse at 0.110 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID70200Binding affinity towards estrogen receptor alpha by [3H]17-beta-estradiol displacement.2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists.
AID112894Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID51049Binding affinity against corticosteroid-binding globulin1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID172991In vivo for antifertility potency in rat at 200 ug/Kg/day1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID113038Uterotrophic effect in mice at 0.4 ug dose(Expt 8)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID112897Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 5)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID212737Binding affinity against testosterone-binding globulin (TeBG)1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID678802TP_TRANSPORTER: drug resistance(SN-38) in BCRP-expressing K562 cells2003Molecular cancer therapeutics, Jan, Volume: 2, Issue:1
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
AID284766Inhibition of 17beta-HSD1 over-expressed in intact HEK293 cells at 10 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID424693Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur phosphorous content at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID291689Effect on lung weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID1724580Antagonist activity at full length human ERbeta receptor assessed as inhibition of estradiol-induced activation incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID137266Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 15.4+/-1.7)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID71139Ratio of displacement of 17-beta-[3H]-estradiol from calf uterine estrogen receptor compared to 17-beta-estradiol after 2 hr incubation1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID424691Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur length at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID284772Inhibition of 17beta-HSD7 over-expressed in intact HEK293 cells at 10 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID113029Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 8)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID130417Antiestrogenic activity in uterotrophic test in mice at 0.1 ug1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
AID113031Uterotrophic effect in mice at 0.231 ug dose (Expt 3)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID112888Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 25 ug1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities, and mammary tumor inhibiting activity.
AID262955Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID424689Antiosteoporosis activity against ovariectomized ICR mouse assessed as dry femur weight at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID284773Inhibition of 17beta-HSD7 over-expressed in intact HEK293 cells at 1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID113036Uterotrophic effect in mice at 0.4 ug dose(Expt 6)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID396110Inhibition of 17beta-HSD1 expressed in HEK 293 cells assessed as conversion of [14C]estrone to [14C]estradiol using NADH2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
AID232475Selectivity ratio for antifertility and estrogenic potencies in rats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
17-Desoxy estrogen analogues.
AID21263Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID51055Binding affinity to human CBG receptor (corticosteroid-binding globulins)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
AID284767Inhibition of 17beta-HSD1 over-expressed in intact HEK293 cells at 1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID70186Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1337729Inhibition of recombinant human CYP1B1 expressed in bacterial microsomes co-expressing P450 reductase using 7-ethyl-O-resorufin as substrate after 45 mins in presence of NADPH by fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
AID679170TP_TRANSPORTER: inhibition of topotecan uptake (Topotecan: 20 uM) in BCRP-expressing K562 cells2004Cancer research, Jun-15, Volume: 64, Issue:12
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
AID291687Effect on phosphorus level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID396108Inhibition of 17beta-HSD1 assessed as conversion of [14C]estradiol to [14C]estrone using NADP+2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
AID424692Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur calcium content at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID212919Binding affinity towards testosterone binding globulin is expressed as log(1/k).1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID71141Ratio of RBA values obtained a with and without DMF at 20h incubation1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers.
AID424687Antiosteoporosis activity against ovariectomized ICR mouse assessed as serum phosphorous level at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID1337728Inhibition of recombinant human CYP1B1 expressed in bacterial microsomes co-expressing P450 reductase at 3 uM using 7-ethyl-O-resorufin as substrate after 45 mins in presence of NADPH by fluorescence assay relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
AID70983Relative binding affinity for estrogen receptor by displacement of [3H]estradiol1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis, receptor binding, and target-tissue uptake of carbon-11 labeled carbamate derivatives of estradiol and hexestrol.
AID113035Uterotrophic effect in mice at 0.4 ug dose(Expt 5)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID424694Antiosteoporosis activity against ovariectomized ICR mouse assessed as mineral content at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID679440TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.04 uM, #Estrone: 100 uM) in OATP-B-expressing HEK293 cells2001Pharmaceutical research, Sep, Volume: 18, Issue:9
Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID112736Anti-uterotrophic effect in mice at 0.4 ug1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydr
AID212931Binding affinity towards human testosterone binding globulin.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID137113Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 12.3+/-3.7)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID197235Oral estrogenic activity in uterotropic assay in rats at 400-4000ng dose1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and biological activity of some 15-oxaestranes.
AID195400Fold induction as increase in BrdU labeling index over estrone treatment alone in lobular-aveolar rat mammary buds by progestin treatment at 3 mg/kg1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists.
AID424690Antiosteoporosis activity against ovariectomized ICR mouse assessed as femur ash weight at 110.3 nmol/kg, po after 30 mins2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID112890Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 5 ug1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities, and mammary tumor inhibiting activity.
AID1724577Displacement of fluormone from GST-tagged ERbeta receptor LBD (unknown origin) measured after 60 mins by TR-FRET competitive binding assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID320274Inhibition of 17beta-HSD1 in human T47D cells assessed as inhibition of transformation of [14C]-estrone into [14C]estrogen at 10 uM after 24 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
AID125481Vaginal cornification test in mice at 0.1 ug; cornified nonnucleated cells present (estrus)1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
AID681147TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing HeLa cells1996The American journal of physiology, Feb, Volume: 270, Issue:2 Pt 2
Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter.
AID566839Selectivity ratio of relative binding affinity for human ERbeta to relative binding affinity for human ERalpha2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds.
AID396111Inhibition of 17beta-HSD1 expressed in HEK 293 cells assessed as conversion of [14C]estrone to [14C]estradiol2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
AID291684Effect on femur ash weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID91474Stimulatory activity against estrogen-dependent alkaline phosphatase expression in Ishikawa cells relative to E22003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID112895Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 3)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID70191Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor alpha.2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID680993TP_TRANSPORTER: inhibition of E1S uptake by Estrone at a concentration of 200uM in membrane vesicles from ABCG2-expressing P388 cells2003The Journal of biological chemistry, Jun-20, Volume: 278, Issue:25
ABCG2 transports sulfated conjugates of steroids and xenobiotics.
AID113033Uterotrophic effect in mice at 0.4 ug dose(Expt 2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID112899Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 7)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID113037Uterotrophic effect in mice at 0.4 ug dose(Expt 7)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID1270809Competitive inhibition of human aromatase extracted from placental microsomes after 5 mins by Dixon plot analysis in presence of [1beta-3H]AD2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID284764Inhibition of 17beta-HSD1 overexpressed in homogenated HEK293 cells at 1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID262950Displacement of [3H]estrone from ER alpha2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID1724578Agonist activity at full length human ERalpha receptor assessed as transcriptional activity incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID291682Effect on serum phosphorus level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID51059Binding affinity to corticosteroid binding globulin1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1724579Antagonist activity at full length human ERalpha receptor assessed as inhibition of estradiol-induced activation incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID112893Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID424702Toxicity in ovariectomized ICR mouse assessed as change in uterine weight at 110.3 nmol/kg, po after 4 weeks2009Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10
3D QSAR of novel estrogen-RGD peptide conjugates: getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT.
AID171528Activity tested for the content of calcium in serum of rat when 18 ug/kg of compound was administered intramuscularly when compared to vehicle2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Studies on the synthesis and anti-Osteoporosis of estrogen-GHRPs linkers.
AID70508Affinity of compound towards human estrogen receptor beta2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase.
AID137122Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 12.4+/-3.7)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID566837Displacement of [3H]estradiol from human ERalpha after 18 to 24 hrs relative to estradiol2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds.
AID1724582Selectivity index, ratio of EC50 for agonist activity at full length human ERalpha to EC50 for agonist activity at full length human ERbeta incubated for 22 to 24 hrs by cell based luciferase reporter gene assay2020Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19
Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol.
AID284775Inhibition of 17beta-HSD12 over-expressed in intact HEK293 cells at 1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID137118Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 12.3+/-3.7)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID440682Activity at human recombinant ERbeta by fluorescence polarization assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
AID284765Inhibition of 17beta-HSD1 over-expressed in homogenated HEK293 cells at 0.1 uM2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.
AID467823Inhibition of His-tagged human 17beta-HSD1 expressed in Escherichia coli by scintillation counting2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
AID231319Ratio of binding affinities at estrogen receptor subtypes alpha and beta.2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Synthesis and structure-activity relationship of 3-arylbenzoxazines as selective estrogen receptor beta agonists.
AID112896Anti-uterotrophic effect in mice at 0.1 ug dose(Expt 4)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
AID566838Displacement of [3H]estradiol from human ERbeta after 18 to 24 hrs relative to estradiol2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds.
AID262957Selectivity for ER beta over ER alpha-mediated transactivation of ERE in HeLa cell luciferase assay2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID69533Relative binding affinity against rat uterine estrogen receptor2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Estradiol-16alpha-carboxylic acid esters as locally active estrogens.
AID260451Inhibition of 17-beta HSD2 in MDA-MB231cells at 10 uM2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
AID113208Uterotrophic activity in mice at 0.4 ug dose1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Mammary tumor inhibiting effect of 3,3'-diacetoxy-alpha, beta-dialkylstilbenes and of related stilbene oxides.
AID291679Increase in body weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID291681Effect on serum calcium level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID680992TP_TRANSPORTER: inhibition of E1S uptake by Estrone at a concentration of 30uM in membrane vesicle from BCRP-expressing K562 cells2003Molecular pharmacology, Sep, Volume: 64, Issue:3
Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
AID137261Uterotrophic effect in mice as relative uterine weight(mg) at 0.4 ug (control = 14.5+/-2.1)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
AID291692Effect on uterus weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1797922Competition-Based Ligand Binding Assay and Transactivation Assay. from Article 10.1021/jm0509389: \\Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.\\2006Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
AID1802486GOAT Activity Assay from Article 10.1021/acs.biochem.6b01008: \\Synthetic Triterpenoid Inhibition of Human Ghrelin O-Acyltransferase: The Involvement of a Functionally Required Cysteine Provides Mechanistic Insight into Ghrelin Acylation.\\2017Biochemistry, 02-21, Volume: 56, Issue:7
Synthetic Triterpenoid Inhibition of Human Ghrelin O-Acyltransferase: The Involvement of a Functionally Required Cysteine Provides Mechanistic Insight into Ghrelin Acylation.
AID1797995ER-alpha Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm015577l: \\Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.\\2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID1797996ER-beta Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm015577l: \\Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.\\2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9,753)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906002 (61.54)18.7374
1990's1017 (10.43)18.2507
2000's1238 (12.69)29.6817
2010's1108 (11.36)24.3611
2020's388 (3.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.49 (24.57)
Research Supply Index9.28 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index109.62 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (60.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials432 (4.21%)5.53%
Reviews279 (2.72%)6.00%
Case Studies113 (1.10%)4.05%
Observational20 (0.19%)0.25%
Other9,422 (91.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Controlled, Single-blinded, Longitudinal, Two-arms, Clinical Study Evaluation of Efficacy/Safety of EVE-PMS Skin-Test Panel -Detecting Sensitivity to Sex Hormones in Women With Premenstrual Syndrome [NCT00866437]Phase 240 participants (Anticipated)Interventional2009-04-30Recruiting
A Phase II Randomized, Two-arms, Single-blind, Cross Controlled Study for Evaluation the Safety and Efficacy of Diagnosis and Treatment of Premenstrual Syndrome by Detecting Skin Reactions Followed by Desensitization to Sex Hormones [NCT00873262]Phase 220 participants (Anticipated)Interventional2009-04-30Recruiting
A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects [NCT00449202]Phase 2100 participants Interventional2006-06-30Active, not recruiting
A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults. [NCT00449254]Phase 224 participants (Anticipated)Interventional2006-10-31Active, not recruiting
A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women [NCT00141557]Phase 2133 participants (Actual)Interventional2004-07-31Terminated(stopped due to Lack of enrollment)
A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women [NCT00141544]Phase 228 participants (Actual)Interventional2004-07-31Terminated(stopped due to Lack of enrollment)
A Multi-Center, Double-Blind, Placebo-Controlled Comparison of Multiple Doses of Esterified Estrogens and Methyltestosterone, in Combination and Alone, in Relieving Vasomotor Symptoms in Postmenopausal Women [NCT00160342]Phase 21,251 participants (Anticipated)Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]